[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1454
1. Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M: Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today; 2005;35(12):1033-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reverse transcription - polymerase chain reaction (RT-PCR) for alpha-fetoprotein (AFP) is used to detect circulating liver cancer cells.
  • The detection of AFP mRNA was significantly correlated with extrahepatic metastasis after primary surgery, and a shorter disease-free survival time (P = 0.0245 each).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Liver Neoplasms / blood. Neoplasm Recurrence, Local / blood. RNA, Messenger / blood. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Bone Marrow / metabolism. Case-Control Studies. Chi-Square Distribution. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. Prognosis. Prospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):649-53 [8596379.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):415-23; discussion 423-5 [7574923.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1418-25 [7527002.001]
  • [Cites] Arch Surg. 2000 Dec;135(12):1456-9 [11115352.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):527-32 [11179482.001]
  • [Cites] Arch Surg. 2000 Feb;135(2):213-8 [10668884.001]
  • [Cites] Dig Dis Sci. 2000 Jul;45(7):1376-82 [10961717.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1749-56 [1919627.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4021-7 [10632334.001]
  • [Cites] Hepatology. 1990 Oct;12 (4 Pt 1):680-7 [1698703.001]
  • [Cites] Hepatology. 1994 Apr;19(4):889-94 [8138262.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):381-6 [10228826.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):919-25 [8884314.001]
  • [Cites] Hepatology. 2002 Apr;35(4):853-60 [11915031.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2772-80 [7954236.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1503-9 [15307868.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):43-50 [9242336.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1064-7 [2556944.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):818-21 [12378622.001]
  • [Cites] Br J Cancer. 1997;76(5):628-33 [9303362.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Apr;16(4):445-51 [11354284.001]
  • [Cites] Br J Cancer. 1997;75(6):928-33 [9062418.001]
  • [Cites] Arch Surg. 2002 Jan;137(1):94-9 [11772225.001]
  • [Cites] Life Sci. 1998;62(21):1973-84 [9619847.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):469-72 [8751199.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2263-7 [1327495.001]
  • [Cites] Surgery. 2002 Jan;131(1):34-43 [11812961.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):500-4 [11118315.001]
  • [Cites] Langenbecks Arch Surg. 2001 Mar;386(2):118-23 [11374044.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1534-9 [1403032.001]
  • [Cites] Cancer. 1995 May 1;75(9):2214-9 [7536120.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1504-9 [1347253.001]
  • (PMID = 16341483.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


2. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • The UICC-TNM classification of malignant liver tumors is applied for both tumor entities.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • In high incidence areas, such as Asia and Africa, HCC is strongly associated with chronic viral hepatitis B and C and liver cirrhosis.
  • But several risk factors including hepatolithiasis, liver fluke infection, and anatomical abnormalities associated with inflammation of the biliary tract have been described.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


3. Zhou XP, Quan ZW, Cong WM, Yang N, Zhang HB, Zhang SH, Yang GS: Micrometastasis in surrounding liver and the minimal length of resection margin of primary liver cancer. World J Gastroenterol; 2007 Sep 7;13(33):4498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micrometastasis in surrounding liver and the minimal length of resection margin of primary liver cancer.
  • AIM: To describe the distribution of micrometastases in the surrounding liver of patients with primary liver cancer (PLC), and to describe the minimal length of resection margin (RM) for hepatectomy.
  • The resected liver specimens were minutely examined to measure the resection margin and to detect the number of daughter tumor nodules, dominant lesions, and macroscopic tumor thrombi inside the lumens of the major venous system.
  • RESULTS: In the retrospective study, 70 micrometastases were found in surrounding liver in 26 of the 120 cases (21.7%).
  • Two hundred and sixty-seven micrometastases were found in surrounding liver in 14 (77.8%) out of 18 cases with macroscopic tumor thrombi or macrosatellites.
  • CONCLUSION: The required minimal length of RM is 5.5 mm and 6 mm respectively to achieve 99% and 100% micrometastasis clearance in surrounding liver of PLC patients without macroscopic tumor thrombi or macrosatellites, and should be greater than 18.5 mm to obtain 99% micrometastasis clearance in surrounding liver of patients with macroscopic tumor thrombi or macrosatellites.
  • [MeSH-major] Hepatectomy. Liver. Liver Neoplasms. Neoplasm Metastasis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724808.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4611585
  •  go-up   go-down


Advertisement
4. Zhang K, Huang Y: [Clinical features and diagnosis of pulmonary lymphangitic carcinomatosis]. Ai Zheng; 2006 Sep;25(9):1127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In PLC group, 20 patients were found with primary lung cancer; 23 patients were found with primary non-pulmonary carcinoma: 9 cases of breast cancer, 8 cases of large intestinal carcinoma, and 6 cases of gastric carcinoma.
  • Extrapulmonary manifestations (metastasis) included 19 cases (44.2%) of lymph nodes to the supraclavicular region, axillary fossa, and post-peritoneal region, 15 cases (34.9%) to the pleura, 9 cases (20.9%) to the bones, 6 cases (14.0%) to the liver, 3 cases (7.0%) to the pericardium, and 3 cases (7.0%) to the brain.
  • CONCLUSIONS: PLC often occurs in patients with primary carcinoma in lung, breast, large intestine, stomach, and so on.
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Carcinoembryonic Antigen / blood. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965655.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


5. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist; 2008 Dec;13(12):1270-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
  • PURPOSE: Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients.
  • The metastatic sites analyzed were the liver in 80 patients (80.8%), lung in seven patients (7.1%), and other sites in 12 patients (12.1%).
  • RESULTS: A KRAS mutation was found in 38 (38.4%) primary tumors and in 36 (36.4%) related metastases.
  • CONCLUSIONS: Our results indicate that the detection of KRAS mutations in either primary or metastatic tumors from patients with CRC is concordant and this assessment could be used to predict response to targeted therapies such as cetuximab and panitumumab.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056857.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Park YB, Lee JW, Cho BS, Min WS, Cheung DY, Kim JI, Cho SH, Park SH, Kim JK, Han SW: Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia. Dig Dis Sci; 2010 Jan;55(1):73-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia.
  • Patients with thrombocytopenia caused by various neoplastic and primary bone marrow diseases are susceptible to major hemorrhage.
  • The incidence of GI bleeding was 6.3% (32 of 508 patients) in adult patients with aplastic anemia.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Risk Factors. Thrombocytopenia / complications. Young Adult


7. Knowles B, Bellamy CO, Oniscu A, Wigmore SJ: Hepatic resection for metastatic endometrioid carcinoma. HPB (Oxford); 2010 Aug;12(6):412-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article describes a tertiary hepatopancreatobiliary unit's experience with hepatic resection for liver metastases from endometrioid primaries.
  • METHODS: Five women in whom liver metastases developed at 11 months to 10 years post-primary resection are presented.
  • RESULTS: Outcomes in this patient series support hepatic resection in the face of isolated liver metastasis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hepatectomy. Hysterectomy. Liver Neoplasms / surgery. Ovarian Neoplasms / surgery. Ovariectomy
  • [MeSH-minor] Adult. Aged. Databases as Topic. Disease-Free Survival. Female. Humans. Middle Aged. Scotland. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):45-51 [9234920.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] J Minim Invasive Gynecol. 2005 May-Jun;12(3):196-200 [15922974.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Cir Esp. 2006 May;79(5):310-2 [16753122.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):524-35 [16998361.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):207-18 [17963007.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):22-7 [18947860.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):28-34 [19010521.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):337-41 [19041126.001]
  • [Cites] Arch Pathol Lab Med. 2009 Nov;133(11):1775-81 [19886711.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):16-21 [12694649.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):399-422 [15228413.001]
  • [Cites] Major Probl Clin Surg. 1977;22:1-342 [839860.001]
  • [Cites] Surg Gynecol Obstet. 1991 Dec;173(6):454-60 [1948602.001]
  • [Cites] J Am Coll Surg. 1998 Nov;187(5):487-93 [9809564.001]
  • (PMID = 20662792.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028582
  •  go-up   go-down


8. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • [MeSH-major] Chromosome Aberrations. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lee HL, Liu YY, Yeh CN, Chiang KC, Chen TC, Jan YY: Primary squamous cell carcinoma of the liver: a successful surgically treated case. World J Gastroenterol; 2006 Sep 7;12(33):5419-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the liver: a successful surgically treated case.
  • Primary squamous cell carcinoma (SCC) of the liver is rare.
  • Primary SCC of the liver has been reported to be associated with hepatic teratoma, hepatic cyst, or hepatolithiasis.
  • Complete remission of poorly differentiated SCC of the liver could be achieved by systemic chemotherapy followed by surgery or remarkably respond to hepatic arterial injection of low dose chemotherapeutic drugs.
  • Here we report the first case of primary SCC of the liver presenting as a solid tumor and receiving successful hepatic resection with 9-mo disease free survival.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Liver / pathology. Liver / ultrasonography. Male. Remission Induction. Treatment Outcome. Ultrasonography


10. Ye YJ, Wang S, Wu J, Shen ZL, Yin MJ, Yang XD, Jiang KW, Zhou J: [Clinicopathological analysis of synchronous hepatic metastases from colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 May;11(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of synchronous hepatic metastases from colorectal cancer].
  • OBJECTIVE: To screen the clinicopathological factors of synchronous hepatic metastases from colorectal cancer for early diagnosis and therapy.
  • METHODS: Clinicopathological data of 367 cases with colorectal cancer from Jan.
  • RESULTS: Out of 367 colorectal cancer cases, there were 56 cases with synchronous hepatic metastases from colorectal cancer, accounting for 15.3%.
  • The primary tumor located in the right colon resulted in more right lobe hepatic metastases than those in the left lobe.
  • CONCLUSION: Peritoneal or pelvic metastases, bowel obstruction, age and serum CEA level are associated with synchronous hepatic metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Young Adult


11. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


12. Wong DW, Lupton SC, Bhatt L, Gross L, Tanière P, Peake DR, Spooner D, Geh JI: Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. Clin Oncol (R Coll Radiol); 2008 Sep;20(7):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
  • MATERIALS AND METHODS: A retrospective audit of the use of imatinib mesylate in GISTs within the Pan-Birmingham Cancer Network was carried out.
  • RESULTS: The most common primary tumour sites were small intestine (19 [49%]) and stomach (12 [31%]).
  • Common sites of metastases were liver (19 [49%]) and peritoneum (12 [31%]).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514495.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


13. Morshed K, Szymański M, Siwiec H, Gołabek W: Laryngeal cancer in farmers from Lublin region of Poland. Ann Agric Environ Med; 2008;15(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal cancer in farmers from Lublin region of Poland.
  • The group included 148 patients with primary laryngeal squamous cell carcinoma (LSCC) diagnosed and treated in our institution in the years 1999-2002.
  • Nearly statistical significance was observed for the N stage (p=0.06) and for primary localisation of the tumour (p=0.05).
  • Distant metastases were observed in 7 (8.3%) of 84 farmers with LSCC, 6 to the lungs and one to the liver.
  • Farmers with larynx cancer had different presentation pattern than other profession patients.
  • The incidence of glottic cancer and well differentiated cancer was higher in farmers than in other professions.
  • The prevalence of larynx cancer in women was significantly lower among farmers than in other professions.
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Poland / epidemiology. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581974.001).
  • [ISSN] 1232-1966
  • [Journal-full-title] Annals of agricultural and environmental medicine : AAEM
  • [ISO-abbreviation] Ann Agric Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


14. Stîngu C, Mitulescu G, Ungureanu C, Popescu I: [Soft tissue reconstruction after total pelvic exenteration]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):389-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During 2000-2006, in General Surgery and Liver Transplantation Fundeni, 73 patients with advanced pelvic cancer and invasive recurrences were operated.
  • We found that complications related to total pelvic exenteration dramatically decreased and primary healing of the perineal wound was superior, facts that correlate with the literature data.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Omentum / transplantation. Pelvic Neoplasms / surgery. Pelvis / surgery. Quality of Life. Rectus Abdominis / transplantation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966934.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


15. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg; 2007 Apr;245(4):597-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.
  • INTRODUCTION: The aim of this study was to evaluate the results of an aggressive strategy in patients presenting peritoneal carcinomatosis (PC) from colorectal cancer with or without liver metastases (LMs) treated with cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • The main endpoints were morbidity, mortality, completeness of cancer resection (CCR), and actuarial survival rates.
  • Three patients had prior to CS + HIPEC, 10 had concomitant minor liver resection, and 3 had differed liver resections (2 right hepatectomies) 2 months after CS + HIPEC.
  • The survival rates were not significantly different between patients who had CS + HIPEC for PC alone (including the primary resection) versus those who had associated LMs resection (median survival, 35.3 versus 36.0 months, P = 0.73).
  • CONCLUSION: Iterative CS + HIPEC is an effective treatment in PC from colorectal cancer.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Liver Neoplasms / secondary. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S118-22 [16399448.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Oct;29(10):1010-3 [16435508.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):632-6 [16621428.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):198-205 [11505065.001]
  • [Cites] Oncology. 2002;63(4):346-52 [12417789.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • [Cites] Scand J Surg. 2003;92(2):178-9 [12841562.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):531-41 [14567016.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):543-59 [14567017.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):165-82 [15000156.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):455-6 [15048746.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):518-21 [15123461.001]
  • [Cites] Br J Surg. 2004 Jun;91(6):747-54 [15164446.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):278-85 [15273552.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Eur J Surg Oncol. 2004 Oct;30(8):864-8 [15336733.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):235-40 [7754629.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] Bull Cancer. 2004 May;91(5):E113-32 [15568226.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):83-6 [15711417.001]
  • [Cites] Cancer Invest. 2005;23(2):155-72 [15813509.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):65-71 [15827780.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):397-9 [15933477.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • (PMID = 17414609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1877034
  •  go-up   go-down


16. Ercolani G, Vetrone G, Grazi GL, Cescon M, Di Gioia P, Ravaioli M, Del Gaudio M, Tuci F, Zanello M, Cucchetti A, D Pinna A: The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients. Minerva Chir; 2009 Dec;64(6):551-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients.
  • AIM: The aim of this study was to evaluate the role of surgery in the treatment of non-colorectal, non-neuroendocrine (NCRNNE) liver metastases.
  • METHODS: One hundred and thirty-four patients undergoing curative liver resection for NCRNNE liver metastases were retrospectively analyzed.
  • The following prognostic factors were analyzed: age (cut-off 50 year old), single vs. multiple nodules, diameter (cut-off 5 cm), disease-free interval less vs. more than one year, type of primary tumor, blood transfusion, major hepatectomy vs. minor hepatectomy.
  • Survival of patients undergoing liver resection for metastatic colorectal cancer was also analyzed to compare the results with the study population.
  • Diameter, disease-free interval and metastases from gastrointestinal cancers were independently related to the survival at the multivariate analysis.
  • Patients with liver metastases from gastrointestinal primary tumors were those with a worse survival (25% and 19% at 3 and 5 years, respectively).
  • CONCLUSIONS: Surgery is an effective treatment for patients with NCRNNE liver metastases, providing satisfactory long-term outcomes with acceptable morbidity and mortality, in particular when excluding patients with gastro-intestinal metastases.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029352.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol; 2005 Aug 14;11(30):4661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
  • METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
  • Only 4 in the 20 cirrhotic liver tissues were found to be weak positive, while no expression of MUC1 was detected in normal liver tissues.
  • Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues.
  • The expressed MUC1 protein, stained in dark brownish or brownish-yellow particles, chiefly localized on the cancer cell membranes or in cytoplasm.
  • CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1
  • [Other-IDs] NLM/ PMC4615407
  •  go-up   go-down


18. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol; 2007 May 1;25(13):1670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
  • METHODS: Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease.
  • The primary end point was response rate (RR).
  • The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only).
  • CONCLUSION: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Quality of Life. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Estrada-Sánchez G, Ochoa-Carrillo FJ, Altamirano-Ley J: [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer]. Cir Cir; 2008 Jul-Aug;76(4):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
  • BACKGROUND: Of women between 15 and 29 years of age, 13.6% will die from breast cancer.
  • For women between 30 and 64 years of age, 19% will die from breast cancer.
  • METHODS: We studied 1728 oncological patients and 295 patients were included, 293 with breast cancer (17%) and two patients with primary breast lymphoma (0.1%).
  • SUVmax for the primary tumor was 4.2 +/- 2.6 SD.
  • Mean SUVmax for patients with primary breast lymphoma were 3.2 and 1.4.
  • Sites of metastases were lymph nodes in the neck (4.4% SUVmax 2.7), internal mammary lymph nodes (5% SUVmax 5.3), mediastinum (8.3% SUVmax 5.0), retroperitoneal (6 % SUVmax 5.4), ipsilateral axilla (94% SUVmax 4.5), contralateral axilla (4.4% SUVmax 2.8), pectoral muscle (10.2% SUVmax 2.6), pleura (4.4% SUVmax 3.9), lung (32.3% SUVmax 2.9), liver (19.1% SUVmax 4.5), bone (36.7%), adrenal gland (4.4% SUVmax 2.4), brain (4.4%), spleen and contralateral breast, one case each.
  • The incidence of a second primary was 4.7%, 2.1% ovarian, 1.4% lung, 0.3% lymphoma, 0.3% endometrium, 0.3% pancreas and 0.3% thyroid.
  • CONCLUSIONS: Mean SUVmax for the primary tumor was similar to that reported in the literature.
  • [MeSH-minor] Adult. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radiography. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Cost-Benefit Analysis. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Hyperplasia. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Mammography. Neoplasms, Multiple Primary / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Thymus Gland / pathology. Thymus Gland / radionuclide imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778536.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Ahmad A, Chen SL, Bilchik AJ: Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg; 2007 Jun;142(6):526-31; discussion 531-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Multimodal treatment consisting of repeated hepatectomy and adjuvant systemic chemotherapy for liver-confined recurrence of colorectal cancer can yield long-term survival comparable with that associated with primary hepatectomy.
  • SETTING: A prospective database at a tertiary referral cancer center.
  • PATIENTS: Review of 274 consecutive liver resections identified 64 patients who underwent resection of hepatic colorectal metastases without ablation followed by adjuvant irinotecan hydrochloride- or oxaliplatin-based systemic chemotherapy.
  • MAIN OUTCOME MEASURES: Median and 5-year overall and disease-free survival after primary and repeated hepatectomy.
  • Multivariate analysis showed that less than 1 year between colectomy and liver resection (P = .001), more than 3 metastases (P = .001), no repeated hepatectomy (P = .01), and lymph node-positive primary colon cancer (P = .02) were independently predictive of worse survival.
  • Of 28 patients (44%) with liver-confined recurrence, 19 (30%) underwent repeated hepatectomy; at median follow-up of 38 months, median and 5-year overall survival after repeated hepatectomy were 48 months and 44%, respectively.
  • In patients with recurrence, median and 5-year overall survival measured from primary hepatectomy were 70 months and 73%, respectively, with repeated hepatectomy vs 43 months and 43%, respectively, without repeated hepatectomy (P = .03).
  • CONCLUSION: Multimodal treatment of recurrent colorectal cancer confined to the liver should begin with consideration of repeated hepatectomy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576888.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ: Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother; 2008 Jan;31(1):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vaccination consisted of autologous cells cultured from primary tumor or resected metastasis, transduced to express B7.1 surface molecule and then irradiated.
  • [MeSH-major] Antigens, CD80 / immunology. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Interleukin-2 / therapeutic use. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Interferon-gamma / metabolism. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / metabolism. Liver / drug effects. Liver / immunology. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Skin / drug effects. Skin / immunology. Skin / pathology. Survival Analysis. Transfection. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157014.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA 82059-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Cancer Vaccines; 0 / Interleukin-2; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


22. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol; 2006 Mar 20;24(9):1395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
  • PURPOSE: Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.
  • The primary end point was survival; secondary end points were response, recurrence, toxicity, quality of life, cost, and the influence of molecular markers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Disease Progression. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Quality of Life. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Oct 1;26(28):4528-9 [18824703.001]
  • (PMID = 16505413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA12449; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA27525; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, Cross SS, Thomson M: Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut; 2007 Jun;56(6):838-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Prospective clinical, pathological and outcome data of patients with colitis-associated Paris class 0-II and Paris class I ALM treated with EMR (primary end points being colorectal cancer development, resection efficacy, metachronous lesion rates and post-resection recurrence rates) were compared with those of sporadic controls.
  • 170 ALMs, 18 dysplasia-associated lesion masses (DALMs) and 16 cancers were diagnosed.
  • 1675 controls were included from our prospective database of patients without CUC who had undergone EMR for sporadic Paris class 0-II and snare polypectomy of Paris type I lesions from 1998 onwards, and were considered to be at moderate to high lifetime risk of colorectal cancer.
  • No statistically significant differences were observed between the CUC study group and controls with respect to age, sex, median number of colonoscopies per patient, median follow-up duration, post-resection complications, median lesional diameter or interval cancer rates.
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1186-92 [16329015.001]
  • [Cites] Int J Oncol. 2000 May;16(5):927-34 [10762628.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2710-9 [11051339.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):371-5 [11868011.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):272-82 [11872049.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):333-8 [12196768.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Endoscopy. 2003 Oct;35(10):845-9 [14551863.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2543-9 [14638361.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Gut. 2004 Feb;53(2):256-60 [14724160.001]
  • [Cites] Gut. 2004 Feb;53(2):284-90 [14724165.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):376-8 [14753220.001]
  • [Cites] Gut. 2004 Mar;53(3):376-80 [14960519.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):642-50 [15114306.001]
  • [Cites] Endoscopy. 2004 Jun;36(6):491-8 [15202044.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):534-41 [15224277.001]
  • [Cites] Gut. 2004 Sep;53(9):1334-9 [15306595.001]
  • [Cites] Gut. 2004 Sep;53 Suppl 5:V1-16 [15306569.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Gastroenterology. 1981 Feb;80(2):366-74 [7450425.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1241-8 [2013371.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gut. 1994 Oct;35(10):1419-23 [7959198.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • (PMID = 17135310.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1954845
  •  go-up   go-down


24. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Muir-Torre syndrome (MTS) is a rare cancer-predisposing syndrome that is autosomal dominantly inherited and characterized by the development of sebaceous skin lesions (adenomas, epitheliomas, basaliomas and carcinomas).
  • These lesions are typically associated with tumors that belong to the spectrum of hereditary nonpolyposis colorectal cancer (HNPCC) (i.e., tumors of the colorectum, endometrium, stomach or ovary).
  • [MeSH-major] Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Germ-Line Mutation. Liver Neoplasms / genetics. MutS Homolog 2 Protein / deficiency. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):567-72 [15235030.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):896-9 [11221877.001]
  • [Cites] Fam Cancer. 2005;4(3):245-8 [16136385.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1159-63 [8118799.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Clin Genet. 2005 Nov;68(5):442-7 [16207212.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):455-9 [16028441.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1112-4 [1310886.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):681-6 [10534628.001]
  • [Cites] EMBO J. 1998 May 1;17 (9):2677-86 [9564049.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


25. Stemmler HJ, Harbeck N, Gröll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, Artmann A, Sommer H, Meerpohl HG, Kiechle M, Heinemann V: Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer. Oncology; 2010;79(3-4):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
  • RESULTS: Since interim analysis showed failure to reach a significant difference for the primary endpoint (hematotoxicity, i.e. leukopenia), the study was closed according to the study protocol (85 of 242 patients).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Metastasis. Middle Aged. Prospective Studies. Survival Rate. Taxoids / administration & dosage. Treatment Outcome. Young Adult


26. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C: 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis; 2010 Oct;12(10 Online):e229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.
  • AIM: Approximately 25% of the patients with colorectal cancer already have liver metastases at diagnosis and another 30% will develop them subsequently.
  • The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed.
  • METHOD: Curative staged resection of liver metastases was performed in 272 consecutive patients.
  • Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed.
  • More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution.
  • CONCLUSION: Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912286.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Zhang F, Wang X, Li X, Kong L, Sun B, Li G, Qian X, Chen F, Wang K, Lu S, Pu L, Lu L: Emergency adult living donor right lobe liver transplantation for fulminant hepatic failure. Front Med China; 2007 Jul;1(3):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency adult living donor right lobe liver transplantation for fulminant hepatic failure.
  • Fulminant hepatitis is fatal in most cases and timely liver transplantation is the only effective treatment.
  • This study evaluates the survival outcomes of patients who underwent living-donor liver transplantation (LDLT) using right lobe liver grafts for fulminant liver failure due to hepatitis B infection.
  • Nine cases of adult right lobe LDLT were performed in our department from September 2002 to August 2005 and the clinical and following-up data were reviewed.
  • The model for end-stage liver disease (MELD) score of these patients ranged from 16 to 42.
  • No primary failure of vascular or biliary complications occurred.
  • Emergency adult living-donor liver transplantation is an effective treatment for fulminant hepatitis patients and is relatively safe for donors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2006 Jun 20;119(12):1003-9 [16805984.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):141-8 [16708358.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):818-25 [12606737.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):301-11; discussion 311-2 [11524583.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S200-4 [11821811.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Transplantation. 1999 Jan 15;67(1):73-7 [9921799.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S64-5 [11084088.001]
  • [Cites] Liver Transpl Surg. 1999 May;5(3):161-5 [10226105.001]
  • [Cites] Transplantation. 2000 Jun 15;69(11):2410-5 [10868650.001]
  • [Cites] Surgery. 2006 Nov;140(5):824-8; discussion 829 [17084727.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):890-5 [11679988.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S66-72 [11084089.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Dec;13(12):881-91 [16491521.001]
  • [Cites] Liver Transpl. 2000 Mar;6(2):163-9 [10719014.001]
  • [Cites] Clin Transplant. 2003 Feb;17(1):37-42 [12588320.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):824-31 [10816625.001]
  • [Cites] Liver Transpl. 2006 Jul;12(7):1049-61 [16799946.001]
  • [Cites] Gastroenterology. 1984 Jun;86(6):1417-20 [6714570.001]
  • (PMID = 24573867.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. de Santibañes E, Fernandez D, Vaccaro C, Quintana GO, Bonadeo F, Pekolj J, Bonofiglio C, Molmenti E: Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg; 2010 Sep;34(9):2133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • BACKGROUND: We evaluated the simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • In all, 185 (25%) of them underwent simultaneous resection of the hepatic lesions and the corresponding primary tumors.
  • CONCLUSIONS: The simultaneous resection of colorectal malignancies and synchronous liver metastases is safe, avoids an additional intervention, can be performed with low morbidity and mortality, and is associated with good oncologic outcomes.
  • [MeSH-major] Colectomy. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / analysis. Female. Humans. Length of Stay. Male. Middle Aged. Patient Selection. Prognosis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Apr;35(4):926-7; author reply 928 [20981543.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Ann Ital Chir. 1996 Nov-Dec;67(6):761-5 [9214268.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] HPB Surg. 1993;6(3):199-203; discussion 203-4 [8387809.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Am J Surg. 1997 Jun;173(6):467-71 [9207156.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):196-202 [12168966.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10 Suppl):S78-84 [11052482.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S35-41 [17981428.001]
  • [Cites] J Surg Oncol. 2001 Sep;78(1):17-21 [11519063.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):129-31 [17256808.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 1997 Nov;226(5):582-6 [9389391.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):872-8 [16671066.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):476-84 [12006929.001]
  • [Cites] Coll Antropol. 2000 Dec;24(2):381-90 [11216406.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Eur J Surg Oncol. 1990 Aug;16(4):360-5 [2379594.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4):399-406 [1650502.001]
  • [Cites] Arch Surg. 1997 Feb;132(2):115-9 [9041911.001]
  • [Cites] Dis Colon Rectum. 1996 Apr;39(4):429-34 [8878504.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1269-84 [15484340.001]
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):124-9 [16231370.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):195-201 [17080238.001]
  • [Cites] Ann Chir. 1996;50(7):507-12; discussion 13-6 [9035419.001]
  • [Cites] Am Surg. 1997 Jul;63(7):605-10 [9202534.001]
  • [Cites] Surgery. 1988 Mar;103(3):278-88 [3278402.001]
  • [Cites] Colorectal Dis. 2009 Jan;11(1):3-10 [18637099.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1310-6 [15484344.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):332-7 [10201774.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):88-93 [9808511.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):282-7 [10587184.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):506-11 [15922887.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1143-50 [17200913.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):956-62 [12905548.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2059-69 [12775730.001]
  • [Cites] Radiology. 2002 Sep;224(3):748-56 [12202709.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):413-34 [9100690.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):7-11 [10770561.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):254-60 [7840389.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):109-15; discussion 116-7 [12559192.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] Dig Surg. 2008;25(6):430-5 [19212115.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • (PMID = 20532766.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


29. Kang TW, Rhim H, Kim EY, Kim YS, Choi D, Lee WJ, Lim HK: Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol; 2009 Jan-Feb;10(1):34-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As well, the primary and secondary technique effectiveness rates in group A and group B were 90% versus 98% (p = 0.29) and 79% versus 91% (p = 0.25), respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burns / etiology. Diaphragm / injuries. Diaphragm / pathology. Female. Humans. Lung Injury / etiology. Male. Middle Aged. Shoulder Pain / etiology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):761-8 [10715043.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1231-3 [10541094.001]
  • [Cites] Radiology. 2002 Mar;222(3):819-23 [11867807.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S103-16; discussion S116-8 [12376604.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):123-34; discussion 134-6 [12533647.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1253-62 [12599233.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1561-2 [12760919.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):695-700 [12933462.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):302-4 [14562984.001]
  • [Cites] J Gastroenterol. 2003;38(10):977-81 [14614605.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):41-52 [14730035.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1224-6 [15100123.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):197-200 [15208138.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):583-8 [15333339.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1417-24 [15505314.001]
  • [Cites] J Neurophysiol. 1991 May;65(5):1042-54 [1869904.001]
  • [Cites] World J Surg. 1992 Jan-Feb;16(1):2-9 [1290261.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):65-6 [9888741.001]
  • [Cites] J Burn Care Rehabil. 2005 May-Jun;26(3):207-27 [15879742.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17(3):541-7 [16567679.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5 Suppl):S269-74 [16632687.001]
  • [Cites] Hepatology. 2006 May;43(5):1101-8 [16628706.001]
  • [Cites] Radiology. 2007 Jun;243(3):877-84 [17517940.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):91-8 [18094298.001]
  • [Cites] AJR Am J Roentgenol. 2008 Apr;190(4):1029-34 [18356451.001]
  • [Cites] Radiology. 2008 Aug;248(2):670-9 [18519740.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2401-3 [11007264.001]
  • (PMID = 19182501.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2647171
  •  go-up   go-down


30. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T: Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol; 2009 Mar;34(3):649-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
  • Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC).
  • It is often difficult to distinguish these liver tumors.
  • In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Glypicans / biosynthesis. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212669.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans
  •  go-up   go-down


31. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T: Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol; 2006 Sep;32(7):756-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
  • AIMS: The degradation of the extracellular matrix is intrinsic to the invasion and progression of cancer.
  • The study aims to investigate if plasma MMP-2, -9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) can be useful markers in the diagnosis and prognosis of colorectal cancer (CRC) metastatic liver disease.
  • METHODS: Fifty-seven patients undergoing liver metastasis operation were followed prospectively.
  • ProMMP-2, -9 and TIMP-1 plasma levels were determined by zymography and ELISA, before and after the resection of liver metastases.
  • Data were compared with those of healthy controls (n=51) and primary CRC patients (n=94).
  • RESULTS: Plasma proMMP-2 levels were lower (P<0.001), and TIMP-1 levels higher (P<0.001) in CRC metastatic liver disease than in healthy controls.
  • If compared to those in primary CRC patients, no differences were found.
  • CONCLUSION: The preoperative plasma proMMP-2, -9 and TIMP-1 levels have no potential value as diagnostic or prognostic markers in CRC liver metastatic disease.
  • [MeSH-major] Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Liver Neoplasms / blood. Liver Neoplasms / secondary. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Tissue Inhibitor of Metalloproteinase-1 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Survival Rate


33. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK: Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg; 2007 Nov;11(11):1498-504; discussion 1504-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.
  • BACKGROUND: Two-stage hepatectomy has been proposed for patients with bilateral colorectal liver metastases (CLM).
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Humans. Length of Stay. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasms, Multiple Primary / surgery. Risk Assessment

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10 ):1261-8 [16947009.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):329-35 [17140759.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):913-9 [15966231.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S7-11 [17449352.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1082-8 [14675719.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Surg. 2004 May;239(5):722-30; discussion 730-2 [15082977.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • (PMID = 17849166.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Liu YJ, Wang GM, Zhang YK, Zhang L, Sun LA, Lin ZM, Zhu TY: [The clinical characteristic of adrenal metastatic tumor]. Zhonghua Wai Ke Za Zhi; 2007 Jan 15;45(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lung and hepatocellular carcinoma were the most common primary tumor of adrenal metastatic tumor, which about 36.9% (38/103) and 42.7% (44/103) of all cases, followed by renal carcinoma 6.8% (7/103), colorectal carcinoma 4.9% (5/103), stomach carcinoma 3.9% (4/103), breast cancer 1.9% (2/103), unknown primary tumor 2.9% (3/103).
  • The mean interval from detection of primary tumor to adrenal metastasis was 9.5 months.
  • CONCLUSIONS: There is no particular presentation of clinic and imaging, diagnosis depending on history, follow-up and the pathological presentation of primary tumor.
  • When the primary tumor could be resected or be well controlled, and there is no other evidence of metastasis, adrenalectomy is recommended.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418043.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Nanashima A, Sumida Y, Abo T, Tobinaga S, Takeshita H, Hidaka S, Yasutake T, Nagayasu T, Mine M, Sawai T: A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma. J Surg Oncol; 2008 Oct 1;98(5):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND AND OBJECTIVES: There is no appropriate grading system for prediction of survival of patients with metastatic liver cancer (MLC) from colorectal carcinoma.
  • METHODS: We compared predictive accuracies of survival of 121 Japanese MLC patients of five systems, including clinical risk score (CRS) proposed by Memorial-Sloan-Kettering-Cancer-Center, original H-number (OHN) by Japanese Society for Cancer of the Colon and Rectum, revised H-number (RHN) and Grade by the same society (GJSCCR), and our modified Grade (MGJSCCR) based on OHN and presence of primary lymph node metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Japan. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Survival Analysis. Survival Rate


36. Limaye PB, Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ, Ochoa ER: Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest; 2008 Aug;88(8):865-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development.
  • Studies in rodent liver have shown that alterations in transcription factor expression determine lineage specification during fetal liver development and signify transdifferentiation of cells of the biliary compartment into 'oval' cells and eventually hepatocytes in adult liver.
  • We examined the cellular localization of hepatocyte- or BEC-associated transcription factors in human fetal and adult liver and in diseases in which transdifferentiation between hepatocytes and biliary cells may play a role.
  • In the normal adult human liver, hepatocyte nuclear factor (HNF)4 alpha and HNF6 appeared exclusively in hepatocytes; HNF1beta, HNF3alpha, and HNF3beta were observed only in BEC.
  • We further examined expression of transcription factors in massive hepatic necrosis and in specific types of chronic liver disease.
  • Similarly, HNF3beta that is expressed only in BEC in normal adult liver was also observed in hepatocytes in primary biliary cirrhosis and chronic biliary obstruction.

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1997 Feb;26(2):343-52 [9059956.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2143-51 [8895481.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):348-53 [9110297.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):905-9 [9327722.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):771-9 [9502419.001]
  • [Cites] Hepatology. 1998 Oct;28(4):980-5 [9755234.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):455-63 [9764994.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):464-74 [10691738.001]
  • [Cites] Mech Dev. 2000 Mar 15;92(1):83-8 [10704889.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):131-42 [11002334.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1393-403 [11158324.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1184-92 [11732008.001]
  • [Cites] Development. 2002 Apr;129(8):1819-28 [11934848.001]
  • [Cites] Development. 2002 Apr;129(8):1829-38 [11934849.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1695-703 [12000721.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):81-7 [12490298.001]
  • [Cites] Semin Liver Dis. 2003 Nov;23(4):373-84 [14722814.001]
  • [Cites] Carcinogenesis. 1987 Nov;8(11):1737-40 [3664968.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1541-7 [2466557.001]
  • [Cites] Arch Pathol Lab Med. 1990 Apr;114(4):403-6 [2322100.001]
  • [Cites] J Cell Biol. 1994 Jul;126(1):223-33 [8027180.001]
  • [Cites] Histol Histopathol. 1995 Apr;10(2):433-56 [7599440.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1243-53 [7557877.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):513-24 [7479372.001]
  • [Cites] Hepatology. 1996 Jan;23(1):62-70 [8550050.001]
  • [Cites] Hepatology. 2005 Mar;41(3):535-44 [15726663.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):944-7 [15959514.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):168-71 [16357531.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Hepatology. 2007 Mar;45(3):716-24 [17326146.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):286-300 [17559071.001]
  • [Cites] Cell. 1996 Feb 23;84(4):575-85 [8598044.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):439-48 [8701983.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • (PMID = 18574450.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA35373; United States / NIDDK NIH HHS / DK / KO8 5K08DK65880; United States / NCI NIH HHS / CA / R01 CA103958; United States / NCI NIH HHS / CA / CA103958-05; United States / NCI NIH HHS / CA / R01 CA103958-05; United States / NCI NIH HHS / CA / R01 CA035373; United States / NCI NIH HHS / CA / CA30241; United States / NCI NIH HHS / CA / R01 CA035373-26; United States / NIDDK NIH HHS / DK / K08 DK065880; United States / NCI NIH HHS / CA / CA035373-26
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS85375; NLM/ PMC2631390
  •  go-up   go-down


37. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymoth A, Sam O, Van der Sande M, Whittle H, Hainaut P, Gambia Hepatitis Intervention Study: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):3216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.
  • Primary hepatocellular carcinoma is the commonest cancer in The Gambia.
  • The Gambia Hepatitis Intervention Study (GHIS) was established in 1986 to evaluate the protective effectiveness of infant hepatitis B immunization in the prevention of chronic liver disease, particularly, hepatocellular carcinoma and cirrhosis later in adult life.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Carcinoma, Hepatocellular / virology. Hepatitis B / complications. Hepatitis B / prevention & control. Hepatitis B Vaccines / therapeutic use. Immunization Programs / organization & administration. Liver Neoplasms / prevention & control. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990765.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Investigator] Hall AJ; Inskip HM; Loik F; Day NE; O'Conor G; Bosch X; Muir CS; Parkin M; Munoz N; Tomatis L; Greenwood B; Whittle H; Ryder R; Oldfield FS; Njie AB; Smith PG; Coursaget P
  •  go-up   go-down


38. Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous hepatic metastases from gastric cancer.
  • Between January 2000 and February 2008, we retrospectively reviewed 7 cases for which RFA was performed for treating metachronous hepatic metastases after resection of the primary gastric adenocarcinoma.
  • Combination therapy such as systemic chemotherapy or hepatic arterial infusion chemotherapy adjuvant to RFA would more reasonable for treating hepatic metastases from gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation / methods. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasms, Second Primary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542847.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Zhang HZ, Dong SX, Zhou ZX, Shao YF: [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases]. Zhonghua Yi Xue Za Zhi; 2007 Jun 5;87(21):1457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases].
  • OBJECTIVE: To explore the strategy to improve the long term survival of liver metastasis of colorectal cancer after surgical treatment.
  • METHODS: The clinical data of 75 patients with liver metastasis of colorectal cancer, 43 males and 32 females, aged 51.4, who received hepatectomy between January 1981 and November 2005, were analyzed.
  • RESULTS: The primary tumor site was colon in 39 cases, and rectum in 36 cases.
  • Liver metastasis was synchronous in 59 patients, and metachronous in 16 patients.
  • 45 patients received simultaneous liver and colorectal resection, 29 patients received metachronous resection, and 1 patient did not receive primary rectal cancer resection.
  • CONCLUSION: Surgical resection of liver metastasis of colorectal cancer significantly prolongs the survival time, and resection of all liver deposits and the extrahepatic disease is the most important factor influencing survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


40. Giovinale M, Fonnesu C, Soriano A, Cerquaglia C, Curigliano V, Verrecchia E, De Socio G, Gasbarrini G, Manna R: Atypical sarcoidosis: case reports and review of the literature. Eur Rev Med Pharmacol Sci; 2009 Mar;13 Suppl 1:37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous inflammation of the spleen and the liver is common in patients with systemic sarcoidosis, while hepatosplenic enlargement is unusual and splenic involvement rare.
  • The second case is a 66-year-old woman with a recent weight loss (8 kg in two months) and alterated liver function tests (AST 61 U/l, ALT 72 U/l, Alkaline phosphatase 748 U/l, g-GT 381 U/l).
  • Since she had a familiar history of colon cancer, abdominal US scan, abdominal CT scan and MRI were performed and showed inter-aorto-caval lymphadenopathies and discreet multiple bilobar hepatic and splenic substitutive lesions, with no signs of primary tumor.
  • This latter required to differentiate liver and/or spleen sarcoidosis from tuberculosis and other infections, primary biliary cirrhosis, metastasis or malignant lymphoma.
  • [MeSH-major] Liver Diseases / complications. Sarcoidosis / complications. Splenic Diseases / complications
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Tomography, X-Ray Computed


41. Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW: Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery; 2005 Oct;138(4):631-7; discussion 637-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study.
  • BACKGROUND: The outcome of restorative proctocolectomy in the setting of chronic ulcerative colitis complicated by primary sclerosing cholangitis (PSC) is not clear.
  • The purpose of this study was to determine the surgical outcome, risk of dysplasia/cancer, morbidity/mortality, long-term results, and functional and quality of life results in patients with inflammatory bowel disease (IBD) and PSC who underwent restorative proctocolectomy with ileal pouch-anal anastomosis and compare them in a case-matched study.
  • Postoperative morbidity, incidence of neoplasia/cancer in the resected specimen, pouchitis, pouch failure, long-term mortality, and 5-year survival rates were compared between the groups.
  • A higher incidence of cancer (14% vs 5%, P = .02) and dysplasia in the resected specimen (40% vs 7%, P < .001), an associated increased risk of postoperative pelvic sepsis (14% vs 5%, P = .02), and higher long-term mortality (35% vs 4%, P < .001) were found in the PSC group compared with control group with no associated PSC.
  • The majority, 13 of 23 (57%), of the deaths in the PSC group were a result of liver disease.
  • CONCLUSIONS: PSC-associated IBD patients after restorative proctocolectomy have a higher risk of neoplasia/cancer in the resected specimen, postoperative pelvic sepsis, and higher long-term mortality.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Infection / etiology. Intestinal Neoplasms / etiology. Male. Middle Aged. Pelvis. Quality of Life. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269291.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Floer M, Binion DG, Nelson VM, Manley S, Wellner M, Sadeghi S, Behmaram B, Sewell C, Otterson MF, Kucharzik T, Rafiee P: Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol; 2008 Sep;295(3):G581-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Control and CD bowel tissues were used to generate primary cultures of muscularis mucosa myofibroblasts, which were assessed directly or following stimulation with TNF-alpha/LPS or H2O2.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2008 Jan;128(1):203-13 [17611581.001]
  • [Cites] Gut. 2007 Jan;56(1):130-9 [17172588.001]
  • [Cites] Ann Rheum Dis. 2000 May;59(5):386-9 [10784522.001]
  • [Cites] Free Radic Biol Med. 2000 Nov 1;29(9):881-8 [11063913.001]
  • [Cites] Genes Dev. 2001 Mar 15;15(6):724-36 [11274057.001]
  • [Cites] Inflamm Bowel Dis. 2001 Aug;7(3):226-36 [11515849.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):17-26 [11882313.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Am J Epidemiol. 2002 Nov 15;156(10):885-902 [12419761.001]
  • [Cites] BMC Gastroenterol. 2001;1:5 [11481030.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):2214-20 [12574395.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8508-15 [12496258.001]
  • [Cites] Thromb Haemost. 2003 Mar;89(3):530-7 [12624638.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):78-85 [12649355.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1679-87 [14680690.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):325-33 [15060836.001]
  • [Cites] Coron Artery Dis. 2004 Aug;15(5):251-8 [15238821.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):257-65 [3335305.001]
  • [Cites] Dis Colon Rectum. 1990 Apr;33(4):271-6 [2323275.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):87-90 [2020666.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):186-90 [8769115.001]
  • [Cites] J Biol Chem. 1998 Jul 31;273(31):19895-901 [9677427.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11301-6 [9736731.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Ann Rheum Dis. 2004 Dec;63(12):1695-9 [15547100.001]
  • [Cites] Semin Vasc Med. 2004 Nov;4(4):347-56 [15861311.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2724-9 [16393226.001]
  • [Cites] J Virol. 2007 Feb;81(3):1492-501 [17108035.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):439-48 [17156147.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 May;292(5):G1323-36 [17218473.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):137-49 [17631138.001]
  • [Cites] Heart. 2007 Aug;93(8):933-9 [17344325.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1692-8; dicussion 1698 [17940830.001]
  • [Cites] Respir Med. 2006 Feb;100(2):202-11 [16005622.001]
  • [Cites] World J Gastroenterol. 2006 Aug 14;12(30):4807-12 [16937461.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):301-7 [17080293.001]
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):378-84 [10711455.001]
  • (PMID = 18635600.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK065948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipopolysaccharides; 0 / MSH3 protein, human; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Tumor Necrosis Factor-alpha; AGG2FN16EV / Simvastatin; BBX060AN9V / Hydrogen Peroxide; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2536780
  •  go-up   go-down


43. Gu YK, Fan WJ, Huang JH, Zhang L, Gao F: [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer]. Ai Zheng; 2007 Oct;26(10):1112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer].
  • BACKGROUND & OBJECTIVE: Lung is the most common organ to which liver cancer cells transfer.
  • For the patients only with lung metastases whose primary liver cancers were in good control, treatment efficacy on lung metastasis is a crucial prognosis factor.
  • This study was to evaluate the efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer.
  • 2006, 17 patients with 37 lung metastatic lesions, whose primary liver cancers were in good control after operation or transcatheter artery chemoembolization (TACE), received CT-guided intra-tumoral dehydrated ethanol injection at Cancer Center of Sun Yat-sen University.
  • All primary liver cancers were in good control during follow-up.
  • CONCLUSION: CT-guided intra-tumoral dehydrated ethanol injection in treating lung metastasis from liver cancer is an effective, micro-invasive method with few complications.
  • [MeSH-major] Ethanol / therapeutic use. Liver Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic / methods. Female. Humans. Injections, Intralesional. Iodized Oil. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927883.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 8001-40-9 / Iodized Oil
  •  go-up   go-down


44. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol; 2010 Jul;30(4):546-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Local production of cytokines within the liver may play a pivotal role in the regulation of pathophysiological processes during inflammation.
  • The purpose of this study was to quantify intrahepatic expression of Th1, Th2, Th17, and Treg-associated cytokines or transcription factors in patients with acute hepatitis B or chronic hepatitis B (CHB) and to analyze their relative roles in the promotion and regulation of hepatitis B virus (HBV)-associated liver diseases.
  • METHODS: Distribution and expression of IL-17, IFN-gamma, IL-4, Foxp3, and other cytokines in liver tissues were detected by immunohistochemistry and real-time quantitative PCR.
  • Patients with hepatitis B were compared with patients with chronic hepatitis C, primary biliary cirrhosis, alcoholic liver cirrhosis, and healthy controls.
  • RESULTS: The frequencies of intrahepatic IL-17 and IFN-gamma-producing cells in patients with HBV-associated liver dysfunction were much higher than that of IL-4 and Foxp3-positive cells.
  • There are more IL-17-producing cells than IFN-gamma-producing cells accumulating in the liver with severe hepatocellular damage.
  • Liver IL-17-producing cell infiltration was positively associated with the grade of liver inflammation in CHB and positively correlated to intrahepatic IL-8 expression (r=0.801, p<0.01) or neutrophil infiltration (r=0.917, p<0.01).
  • Inappropriate, excessive, and non-specific Th17 and Th1 effector responses may be involved in the pathogenesis of HBV-associated liver inflammation and hepatocellular damage.
  • Th17 response, especially, may exacerbate the inflammatory processes leading to liver failure.
  • IL-17-mediating liver neutrophil recruitment via induction of IL-8 may be one potential mechanism of liver injury in patients with hepatitis B.
  • An improved understanding of the factors that influence the differentiation and function of these cell types in vivo will be of great importance to the future development of immune therapies in HBV-associated liver disease.
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. Case-Control Studies. Cytokines / biosynthesis. Female. Humans. Liver / immunology. Liver / metabolism. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Aug;79(15):9369-80 [16014900.001]
  • [Cites] Annu Rev Immunol. 1995;13:251-76 [7612223.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):541-51 [9646176.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3494-502 [18830757.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S13-21 [19399811.001]
  • [Cites] Hepatology. 2010 Jan;51(1):81-91 [19842207.001]
  • [Cites] Hepatology. 2009 Feb;49(2):646-57 [19177575.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Annu Rev Immunol. 1995;13:29-60 [7612225.001]
  • [Cites] Liver Int. 2006 Oct;26(8):912-9 [16953830.001]
  • [Cites] Annu Rev Immunol. 2009;27:485-517 [19132915.001]
  • [Cites] Hepatology. 1997 Apr;25(4):1022-7 [9096614.001]
  • [Cites] J Med Virol. 2003 Nov;71(3):376-84 [12966542.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6503-9 [10352265.001]
  • [Cites] Int Arch Allergy Immunol. 2001 Nov;126(3):179-84 [11752873.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S45-55 [19399792.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3025-33 [9185527.001]
  • [Cites] Annu Rev Immunol. 2009;27:147-63 [19302037.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):215-29 [15738952.001]
  • [Cites] Clin Liver Dis. 2007 Nov;11(4):727-59, vii-viii [17981227.001]
  • [Cites] Hepatology. 1995 Jul;22(1):61-8 [7601434.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Hepatol Res. 2007 Apr;37(4):248-54 [17397512.001]
  • [Cites] Antivir Ther. 1998;3(Suppl 3):13-24 [10726052.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2010-7 [19244111.001]
  • [Cites] Clin Microbiol Infect. 2005 Jan;11(1):52-6 [15649304.001]
  • [Cites] J Autoimmun. 2009 Feb;32(1):43-51 [19101114.001]
  • [Cites] J Hepatol. 2009 May;50(5):980-9 [19329213.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2347-52 [9973514.001]
  • [Cites] Immunol Rev. 2008 Jun;223:87-113 [18613831.001]
  • [Cites] Gastroenterology. 1999 Sep;117(3):645-52 [10464141.001]
  • (PMID = 20393789.001).
  • [ISSN] 1573-2592
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-17; 0 / Transcription Factors
  •  go-up   go-down


45. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


46. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In PTC, COX-2 and iNOS were significantly overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expression was increased in patients with a large primary tumor (p=0.028).
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


47. Tarnowski M, Sieron AL: Adult stem cells and their ability to differentiate. Med Sci Monit; 2006 Aug;12(8):RA154-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stem cells and their ability to differentiate.
  • This is a review of the current status of knowledge on adult stem cells as well as the criteria and evidence for their potential to transform into different cell types and cell lineages.
  • Reports on stem cell sources, focusing on tissues from adult subjects, were also investigated.
  • The question is still open about the characteristics of the primary stem cell.
  • Recent reports on cases of cancer in patients subjected to stem cell therapy are yet another controversial issue looked into in this review, although the pros and cons emerging from the results of published studies still do not provide satisfying evidence to fully understand this issue.
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Humans. Liver Regeneration / physiology. Muscle, Skeletal / cytology. Nerve Tissue / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865077.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 122
  •  go-up   go-down


48. Liu NN, Shen DL, Chen XQ, He YL: [Clinical analysis of 355 patients with bone metastasis of malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary tumors were lung cancer in men and breast cancer in women.
  • Among them, it was 34.9 months in prostate cancer and 4.6 months in hepatocellular carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / secondary. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Pain / etiology. Pain Management. Prostatic Neoplasms / pathology. Quality of Life. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450589.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Sun YL, Yin SY, Xie HY, Zhou L, Xue F, Wu LM, Gao F, Zheng SS: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 1):1280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Recent investigations demonstrate that adult stem cells may be targets for malignant transformation and that the stem-like cells in diseased livers possess the capacity of tumorigenicity in animal models.
  • METHODS: Twenty surgically resected HCCs and corresponding adjacent tissues as well as 10 cirrhotic liver tissues were collected and immunohistochemical staining were performed to detect the expression of CD34, Thy-1, CD133, and c-kit.
  • Then the non-cancerous tissues were transplanted into immunodeficient mice and the characteristics of the cells from primary tissue cultures were explored in vitro.
  • CONCLUSION: Our results suggest that the stem-like cells in cirrhotic livers possess the capacity of tumorigenicity and may contain candidates for HCC cancer stem cells.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Hepatitis B, Chronic / complications. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466286.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Maluccio MA, Covey AM, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, DeMatteo R, Brown KT: Treatment of metastatic sarcoma to the liver with bland embolization. Cancer; 2006 Oct 1;107(7):1617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic sarcoma to the liver with bland embolization.
  • BACKGROUND: The authors evaluated the impact of bland particle embolization on survival in patients with metastatic sarcoma to the liver.
  • METHODS: Twenty-four patients with liver-dominant metastases from sarcoma were treated with particle embolization from 1996 to 2002.
  • Primary tumors included 16 gastrointestinal stromal tumors (GISTs), 7 intestinal leiomyosarcomas, and 1 liposarcoma.
  • RESULTS: Nineteen patients had metachronous liver metastases, and the median disease-free interval was 22 months (range 10-156 months) from resection of the primary tumor.
  • Ten patients underwent prior liver resection for metastatic disease.
  • CONCLUSIONS: Bland embolization was efficacious in some patients with metastatic sarcoma to the liver.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Benzamides. Female. Humans. Imatinib Mesylate. Magnetic Resonance Imaging. Male. Middle Aged. Piperazines / administration & dosage. Polyvinyl Alcohol / administration & dosage. Pyrimidines / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955508.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


51. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S: The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med; 2010 Aug;51(8):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
  • Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for treating primary and metastatic liver cancer, requires appropriate planning to maximize its therapeutic response and minimize its side effects. (99m)Tc-macroaggregated albumin (MAA) scanning should precede the therapy to detect any extrahepatic shunting to the lung or gastrointestinal tract.
  • METHODS: Ninety diagnostic hepatic angiograms with (99m)Tc-MAA were obtained for 76 patients with different types of cancer.
  • [MeSH-major] Liver / radionuclide imaging. Liver Circulation / physiology. Liver Neoplasms / drug therapy. Liver Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Abdomen / radionuclide imaging. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Embolization, Therapeutic. Female. Gallbladder / metabolism. Gallbladder / radionuclide imaging. Humans. Image Interpretation, Computer-Assisted. Male. Microspheres. Middle Aged. Patient Care Planning. Radionuclide Angiography. Reference Standards. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660379.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / Yttrium Radioisotopes
  •  go-up   go-down


52. Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC: Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer; 2007 Apr;43(6):1076-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area.
  • This study used a large-scale cancer database in determining the survival prognostic factors among primary liver cancer (PLC) subjects.
  • Particularly, subjects with adenocarcinoma and CC were more likely to die in other metastatic cancer.
  • [MeSH-major] Endemic Diseases / statistics & numerical data. Liver Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adult. Age Distribution. Aged. Carcinoma, Hepatocellular / mortality. Cause of Death. Cholangiocarcinoma / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Distribution. Survival Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329095.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Iancu C, Mocan LC, Todea-Iancu D, Mocan T, Acalovschi I, Ionescu D, Zaharie FV, Osian G, Puia CI, Muntean V: Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis; 2008 Sep;17(3):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer.
  • AIM: To identify the risk, the host-related prognostic factors and their predictive value for anastomotic leakage after colorectal resections following cancer.
  • METHOD: 993 patients who underwent large bowel resection and primary anastomosis above 12 centimeters from the anal verge, without a temporary or permanent stoma at the Surgical Hospital No.3 (Cluj-Napoca, Romania) were retrospectively reviewed.
  • CONCLUSION. A serum protein level lower than 5.5 g/dl and serum hemoglobin lower than 9.4 g/dl could be considered as host-related predictive markers for anastomotic leak in large bowel resections for cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / complications. Blood Proteins / analysis. Female. Hemoglobins / analysis. Humans. Hypoproteinemia / complications. Logistic Models. Male. Middle Aged. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836623.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Hemoglobins
  •  go-up   go-down


54. Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J, Miyagawa S: Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy; 2006;52(6):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
  • BACKGROUND: This study was designed to examine the efficacy and compliance of S-1 for the patients with peritoneal metastasis of gastric cancer.
  • METHODS: Sixteen consecutive patients with peritoneal metastasis of gastric cancer were treated with S-1.
  • We elucidated some factors to prolong the survival of the patients treated with S-1 for peritoneal metastasis: peritoneal metastasis without other distant metastases, the combination of S-1 treatment and gastrectomy, and low expression of thymidine phosphorylase mRNA in primary tumors.
  • CONCLUSIONS: S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Combinations. Female. Gastrectomy. Humans. Intestinal Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Orotate Phosphoribosyltransferase / metabolism. Patient Compliance. Survival Rate. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008790.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


55. Medine CN, Greenhough S, Hay DC: Role of stem-cell-derived hepatic endoderm in human drug discovery. Biochem Soc Trans; 2010 Aug;38(4):1033-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the safety evaluation process is hindered by the availability and quality of primary human liver models with which to study drug toxicity.
  • In an attempt to overcome this limitation, research has focused on deriving human hepatocytes from a number of sources, including progenitors from fetal and adult liver, human cell lines derived from liver tumours, immortalized human hepatocytes and pluripotent stem cells.
  • The major hurdles in developing scalable and high-fidelity human hepatocytes from hepatic cell lines and fetal and adult progenitors have been limited organ availability, homogeneous cell purification, short-term cell culture, and the rapid loss of hepatocyte phenotype and function in culture.
  • Moreover, stem-cell-derived hepatic endoderm displays many of the functional attributes of primary human hepatocytes.
  • Our research is now focused on developing defined culture systems and improving cell culture microenvironments in order to improve our understanding of the mechanisms regulating human liver development.
  • [MeSH-major] Drug Discovery / methods. Embryonic Stem Cells / physiology. Endoderm / physiology. Liver / embryology
  • [MeSH-minor] Adult. Cell Culture Techniques / standards. Humans. Induced Pluripotent Stem Cells / cytology. Induced Pluripotent Stem Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658999.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


56. Fiaschetti V, Fiori R, Gaspari E, Crusco S, Simonetti G: Mixed hepatoblastoma in a young male adult: a case report and literature review. Case Rep Med; 2010;2010:919457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed hepatoblastoma in a young male adult: a case report and literature review.
  • Hepatoblastoma (HB) is a rare malignant tumour of the liver and usually occurs in the first three years of life.
  • Most of these tumours arise in the embryo; hence it seems to be unusual that hepatoblastoma occurs in adults and is an exceptional cause of primary malignant liver tumour in adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113306.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2990241
  •  go-up   go-down


57. Zhang M, Li B, Yan LN, Yin F, Wen TF, Zeng Y, Zhao JC, Ma YK: Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol; 2008 Feb 28;14(8):1280-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.
  • METHODS: We retrospectively examined a cohort of 150 consecutive primary cadaveric liver transplants with HCC in our center over 6 years.
  • The predictive power of a new model and the model for end stage liver disease was compared by the receiver operating characteristic curve.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Hepatitis B / complications. Hepatitis B / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cell Survival. Cohort Studies. Female. Humans. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies


58. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health; 2007 Sep;38(5):881-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate and compare the presence of Helicobacter pylori VacA in primary liver cancer specimens (12 hepatocellular carcinoma and 6 cholangiocarcinoma) and control liver specimens (7 non-primary liver cancer) from Thai patients who underwent liver resection, H. pylori VacA gene was assayed in extracted DNA by real-time polymerase chain reaction.
  • The selected amplicons revealed high homology compared with H. pylori VacA sequence. H. pylori VacA gene was detected in all primary liver cancer specimens and in 71% (5/7) of control liver specimens.
  • [MeSH-major] Bacterial Proteins / genetics. Carcinoma, Hepatocellular / microbiology. Cholangiocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / genetics. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction / methods. Thailand

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041306.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori
  •  go-up   go-down


59. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Predictors of recurrence were older age, pretransplant cancer antigen (CA) 19-9 >100 U/ml, prior cholecystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineural invasion in explant.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • Prolonged staging-to-OLT intervals for patients transplanted after implementation of model for end-stage liver disease (MELD) showed a trend toward increased recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


60. Mori M, Naruto T, Imagawa T, Murata T, Takei S, Tomiita M, Itoh Y, Fujikawa S, Yokota S: Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod Rheumatol; 2009;19(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement.
  • Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary lesions, are unlikely to be severe at the low MTX doses that are administered.
  • In Japan, MTX was granted approval in 1999 by the then Ministry of Health and Welfare specifically for treating rheumatoid arthritis in adult patients, allowing it be generally used in medical institutions for patients having National Health Insurance.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):763-9 [10717011.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2007 Oct 10;96(10):2226-34 [18044160.001]
  • [Cites] J Rheumatol. 2000 Aug;27(8):1830-3 [10955319.001]
  • [Cites] Ann Rheum Dis. 2000 Nov;59 Suppl 1:i21-7 [11053081.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD003129 [11687037.001]
  • [Cites] Ryumachi. 2002 Feb;42(1):76-9 [11925910.001]
  • [Cites] Arch Dis Child. 2003 Mar;88(3):197-200 [12598376.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2191-201 [15248217.001]
  • [Cites] Ann Rheum Dis. 2004 Sep;63(9):1128-30 [15308522.001]
  • [Cites] Lancet. 1980 Nov 1;2(8201):944-6 [6107590.001]
  • [Cites] J Rheumatol. 1982 Jan-Feb;9(1):109-13 [7045358.001]
  • [Cites] Cancer Res. 1983 May;43(5):2342-5 [6572562.001]
  • [Cites] Arthritis Rheum. 1989 Jun;32(6):677-81 [2735961.001]
  • [Cites] J Rheumatol. 1990 Nov;17(11):1469-73 [2273487.001]
  • [Cites] N Engl J Med. 1992 Apr 16;326(16):1043-9 [1549149.001]
  • [Cites] Br J Rheumatol. 1993 Jan;32(1):73-7 [8422565.001]
  • [Cites] Semin Arthritis Rheum. 1993 Aug;23(1):34-46 [8235664.001]
  • [Cites] J Rheumatol. 1993 Sep;20(9):1573-7 [8164218.001]
  • [Cites] Eur J Clin Pharmacol. 1995;47(6):507-11 [7768253.001]
  • [Cites] J Rheumatol. 1995 Aug;22(8):1570-3 [7473485.001]
  • [Cites] Acta Paediatr Jpn. 1997 Apr;39(2):242-4 [9141265.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Therapie. 1997 Mar-Apr;52(2):129-32 [9231507.001]
  • [Cites] J Rheumatol. 1997 Nov;24(11):2230-2 [9375889.001]
  • [Cites] Ann Rheum Dis. 1998 Jan;57(1):38-41 [9536821.001]
  • [Cites] J Pediatr. 1998 Aug;133(2):179-80 [9709702.001]
  • [Cites] Arthritis Rheum. 1998 Sep;41(9):1552-63 [9751087.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1655-66 [15843668.001]
  • [Cites] Arthritis Rheum. 2000 Aug;43(8):1849-57 [10943876.001]
  • (PMID = 18815725.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2638602
  •  go-up   go-down


61. Oshima T, Kawasaki T, Ohashi R, Hasegawa G, Jiang S, Umezu H, Aoyagi Y, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M: Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol Int; 2007 Feb;57(2):82-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis.
  • Liver metastases are the most critical prognostic factors for patients with colorectal carcinomas (CRC).
  • It has been reported that the dysregulation of hepatocyte nuclear factor-4alpha (HNF4alpha) expression is linked to the development of CRC, gastric cancer and hepatocellular carcinoma.
  • Immunohistochemically, P1, P2, MUC1 and CD10 expression were evaluated in 63 cases of primary CRC.
  • There was a relationship between the loss of P1 expression and metachronous liver metastases, and the survival rate of the P1-negative patients without liver metastasis at the time of the primary CRC resection tended to be worse than that of the P1-positive patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Down-Regulation / physiology. Hepatocyte Nuclear Factor 4 / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Mucin-1 / genetics. Mucin-1 / metabolism. Neprilysin / genetics. Neprilysin / metabolism. Prognosis. Promoter Regions, Genetic / genetics. Promoter Regions, Genetic / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300672.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / Mucin-1; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


62. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI: Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg; 2010 May;210(5):744-52, 752-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.
  • BACKGROUND: This study analyzes factors associated with differences in long-term outcomes after hepatic resection for metastatic colorectal cancer over time.
  • STUDY DESIGN: Sixteen-hundred consecutive patients undergoing hepatic resection for metastatic colorectal cancer between 1985 and 2004 were analyzed retrospectively.
  • There were no differences in age, Clinical Risk Score, or number of hepatic metastases between the 2 groups; however, more recently treated patients (era II) had more lymph node-positive primary tumors, shorter disease-free intervals, more extrahepatic disease, and smaller tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / mortality. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


63. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol; 2005 Sep 20;23(27):6657-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
  • PURPOSE: Epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs).
  • METHODS: The primary objective of this study was to determine the proportion of patients with advanced HCC who were progression-free at 6 months.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Neoplasm Invasiveness / pathology. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N0-1 CM17104
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


64. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP: Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy; 2007 Dec;27(12):1644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
  • STUDY OBJECTIVES: To assess the effectiveness and tolerability of caspofungin as primary prophylaxis against invasive fungal infections in stem cell transplant recipients who are poor candidates for triazole or lipid amphotericin B prophylaxis due to renal or hepatic dysfunction, and to determine whether any patient characteristics are independently associated with an increased risk of breakthrough invasive fungal infection during caspofungin prophylaxis.
  • SETTING: Tertiary care comprehensive cancer center.
  • PATIENTS: One hundred twenty-three adult stem cell transplant recipients who received caspofungin 35-50 mg/day for up to 100 days after transplantation as primary antifungal prophylaxis between January 1, 2002, and June 30, 2005.
  • CONCLUSION: Caspofungin seems to be an effective and well-tolerated option for primary antifungal prophylaxis in the highly immunosuppressed stem cell transplant patient population.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / adverse effects. Cancer Care Facilities. Female. Graft vs Host Disease / etiology. Humans. Infliximab. Liver Failure / complications. Male. Middle Aged. Multivariate Analysis. Opportunistic Infections / microbiology. Opportunistic Infections / prevention & control. Pseudomonas Infections / complications. Renal Insufficiency / complications. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041885.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Immunosuppressive Agents; B72HH48FLU / Infliximab; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


65. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P < .0001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


66. Park SS, Kim CS, Mok YJ, Kim SJ, Kim HI: Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy. Scand J Gastroenterol; 2005 Apr;40(4):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy.
  • OBJECTIVE: Gastric cancer confined to the muscularis propria (mp) has a favorable prognosis, but still belongs to the advanced category.
  • Many oncologists have difficulties in selecting treatment modalities owing to the confused situation of mp cancer.
  • To clarify the therapeutic strategy, the clinicopathological characteristics were investigated, and the risk factors, of this intermediate-stage gastric cancer, evaluated.
  • MATERIAL AND METHODS: A total of 155 patients who underwent curative resection for primary gastric cancer between 1993 and 2001 were diagnosed with mp cancer.
  • A multivariate analysis disclosed only lymphatic metastasis as an independent risk factor for recurrence of mp cancer.
  • Hematogenous metastasis accounted for 37% of the recurrent patterns, and the liver (83.3%) was the most common organ.
  • The 5-year survival rate of all mp cancer patients was 80.9%, but that of patients with recurrent disease was 19.2%.
  • CONCLUSIONS: Lymph node metastasis is the only significant risk factor of mp cancer.
  • On the other hand, patients with mp cancer without lymph node involvement have an excellent prognosis and could be candidates for laparoscopic gastric surgery.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028440.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


67. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K: Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol; 2008;43(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risks and patterns of intrahepatic distant recurrence (IDR) of a single, primary HCC lesion after radiofrequency (RF) ablation were examined.
  • METHODS: Ninety patients with a single primary HCC lesion of less than 3 cm who had complete RF ablation were enrolled in the study.
  • [MeSH-major] Bile Duct Neoplasms / secondary. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / secondary. Catheter Ablation / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Magnetic Resonance Imaging. Male. Middle Aged. Proportional Hazards Models. Protein Precursors / blood. Prothrombin. Retrospective Studies. Risk Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Dec;40(6):1396-405 [15565571.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1714-23 [15578509.001]
  • [Cites] J Hepatol. 2000 Feb;32(2):269-78 [10707867.001]
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):688-94 [9024706.001]
  • [Cites] AJR Am J Roentgenol. 2007 Feb;188(2):480-8 [17242258.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):114-7 [1714267.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1216-23 [11093727.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1501-8 [9118030.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Am J Surg. 1992 Feb;163(2):251-6 [1371207.001]
  • [Cites] Hepatol Res. 2005 Mar;31(3):172-7 [15792641.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Hepatology. 1992 May;15(5):948-63 [1314774.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):488-94 [8392955.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):810-9 [2439190.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] Abdom Imaging. 2001 Jul-Aug;26(4):375-83 [11441549.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):321-8 [16495695.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):373-82 [11882759.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1682-90 [10547540.001]
  • [Cites] Hepatology. 1997 Jan;25(1):87-92 [8985270.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):913-9 [1310434.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):570-5 [11394657.001]
  • [Cites] Hepatology. 1992 Sep;16(3):694-701 [1324215.001]
  • [Cites] Eur J Radiol. 2006 Sep;59(3):432-41 [16690240.001]
  • [Cites] Cancer. 1994 May 15;73(10):2464-71 [7513601.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):949-56 [11251946.001]
  • (PMID = 18297439.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


68. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M: The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol; 2008 Jan;64(1):31-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analyses in vitro using human liver microsomes and recombinant enzymes showed that erlotinib was metabolized primarily by CYP3A4, with a secondary contribution from CYP1A2.
  • This is consistent with the SimCYP prediction of a two-fold increase in erlotinib AUC, further validating a primary (approximately 70%) role of CYP3A4 in erlotinib elimination.
  • [MeSH-minor] Adolescent. Adult. Aged. Area Under Curve. Computer Simulation. Cytochrome P-450 CYP3A Inhibitors. Drug Interactions. Erlotinib Hydrochloride. Forecasting. Humans. Ketoconazole / pharmacology. Male. Microsomes, Liver / metabolism. Middle Aged

  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):387-412 [9755288.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Xenobiotica. 2006 Jun;36(6):473-97 [16769646.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):503-12 [15166626.001]
  • [Cites] Drug Metab Dispos. 2002 Dec;30(12 ):1497-503 [12433825.001]
  • [Cites] J Biol Chem. 1964 Jul;239:2370-8 [14209971.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2544-55 [15753462.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jan;4(1):13-4 [15690599.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3267-79 [11432895.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Eur J Pharm Sci. 2001 Jul;13(4):417-28 [11480400.001]
  • [Cites] Biochem Pharmacol. 1994 Apr 29;47(9):1469-79 [8185657.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1572-8 [15746062.001]
  • [Cites] Eur J Pharm Sci. 2005 Nov;26(3-4):334-40 [16137870.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Drug Metab Dispos. 2000 Sep;28(9):1031-7 [10950845.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Jun;11(6):755-68 [12036420.001]
  • [Cites] Mol Cancer Ther. 2002 Aug;1(10):777-83 [12492110.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Nov;291(2):739-48 [10525095.001]
  • (PMID = 18000659.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytochrome P-450 CYP3A Inhibitors; 0 / Enzyme Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; R9400W927I / Ketoconazole
  •  go-up   go-down


69. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R, Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics: Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep; 2009 Sep 04;58(RR-11):1-166
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topic areas covered for each OI include a brief description of the epidemiology, clinical presentation, and diagnosis of the OI in children; prevention of exposure; prevention of disease by chemoprophylaxis and/or vaccination; discontinuation of primary prophylaxis after immune reconstitution; treatment of disease; monitoring for adverse effects during treatment; management of treatment failure; prevention of disease recurrence; and discontinuation of secondary prophylaxis after immune reconstitution.
  • A separate document about preventing and treating of OIs among HIV-infected adults and postpubertal adolescents (Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents) was prepared by a working group of adult HIV and infectious disease specialists.
  • In addition, HIV-infected women or HIV-infected family members coinfected with certain opportunistic pathogens might be more likely to transmit these infections horizontally to their children, resulting in increased likelihood of primary acquisition of such infections in the young child.
  • Although guidelines for postpubertal adolescents can be found in the adult OI guidelines, drug pharmacokinetics and response to treatment may differ for younger prepubertal or pubertal adolescents.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immune Reconstitution Inflammatory Syndrome / diagnosis. Immune Reconstitution Inflammatory Syndrome / drug therapy. Immunization Schedule. Infant. Infant, Newborn. Male. Pregnancy. Recurrence. Treatment Failure. United States / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • HIV InSite. treatment guidelines - Aspergillosis and HIV .
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Rev Respir Dis. 1993 Feb;147(2):420-4 [8430968.001]
  • [Cites] Pediatr Infect Dis J. 2001 Oct;20(10):988-92 [11642634.001]
  • [Cites] JAMA. 1993 Jul 28;270(4):470-3 [8320786.001]
  • [Cites] Semin Liver Dis. 2007 Aug;27(3):295-311 [17682976.001]
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):296-7 [10629092.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] J Pediatr. 1986 Feb;108(2):224-7 [3944707.001]
  • [Cites] Antimicrob Agents Chemother. 1988 Jul;32(7):1057-60 [3263834.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):176-82 [17305883.001]
  • [Cites] Pediatr Infect Dis J. 1999 Sep;18(9):827-31 [10493348.001]
  • [Cites] J Infect Dis. 1999 Jan;179(1):234-6 [9841845.001]
  • [Cites] Lancet. 2004 Nov 6-12;364(9446):1678-83 [15530628.001]
  • [Cites] Clin Infect Dis. 2003 May 15;36(10):1221-8 [12746765.001]
  • [Cites] AIDS. 2002 May 3;16(7):1045-9 [11953471.001]
  • [Cites] JAMA. 2006 Aug 23;296(8):964-73 [16926356.001]
  • [Cites] Herpes. 2003 Dec;10(3):66-71 [14759338.001]
  • [Cites] N Engl J Med. 1994 May 12;330(19):1356-60 [8152447.001]
  • [Cites] Hepatology. 2001 Aug;34(2):223-9 [11481604.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):548-58 [16421800.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S56-60 [16819403.001]
  • [Cites] J Pediatr. 2003 Jul;143(1):54-9 [12915824.001]
  • [Cites] Am J Obstet Gynecol. 1991 May;164(5 Pt 1):1303-6 [2035573.001]
  • [Cites] J Clin Microbiol. 1993 Nov;31(11):2952-9 [8263181.001]
  • [Cites] Curr Infect Dis Rep. 2007 Nov;9(6):448-56 [17999880.001]
  • [Cites] N Engl J Med. 1987 Oct 29;317(18):1105-8 [3657878.001]
  • [Cites] Indian J Gastroenterol. 2006 May-Jun;25(3):136-9 [16877826.001]
  • [Cites] MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34 [16557217.001]
  • [Cites] Pediatr Infect Dis J. 2006 Oct;25(10):920-9 [17006288.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):628-33 [16177885.001]
  • [Cites] Clin Infect Dis. 1999 Feb;28(2):309-13 [10064249.001]
  • [Cites] Clin Infect Dis. 1996 Feb;22(2):268-75 [8838183.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):297-307 [15018859.001]
  • [Cites] Am J Med. 1993 Aug;95(2):177-87 [8395142.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):297-306 [17563740.001]
  • [Cites] Am J Ophthalmol. 2004 Apr;137(4):636-8 [15059701.001]
  • [Cites] Proc Am Thorac Soc. 2006 Nov;3(8):655-64 [17065370.001]
  • [Cites] Int J Tuberc Lung Dis. 2007 Apr;11(4):417-23 [17394688.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] Arch Dis Child. 1997 Feb;76(2):124-8 [9068301.001]
  • [Cites] Clin Infect Dis. 2006 Dec 15;43(12):1499-539 [17109284.001]
  • [Cites] JAMA. 1999 Nov 3;282(17):1633-7 [10553789.001]
  • [Cites] Arch Dis Child. 1994 Mar;70(3):241-4 [8135571.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):240-6 [11920787.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):531-41 [7756472.001]
  • [Cites] AIDS. 2000 May 26;14(8):1041-9 [10853987.001]
  • [Cites] Semin Liver Dis. 2005;25 Suppl 1:9-19 [16103977.001]
  • [Cites] N Engl J Med. 1991 Feb 28;324(9):580-4 [1992319.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1047-52 [12684918.001]
  • [Cites] Pediatr Infect Dis J. 2005 May;24(5):450-2 [15876946.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Clin Infect Dis. 1998 Jun;26(6):1368-73 [9636865.001]
  • [Cites] J Infect Dis. 1999 Dec;180(6):1809-18 [10558935.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):929-42; quiz 943-5 [17110216.001]
  • [Cites] Clin Infect Dis. 1993 Feb;16(2):208-12 [8382963.001]
  • [Cites] N Engl J Med. 2001 May 3;344(18):1366-71 [11333993.001]
  • [Cites] Afr Health Sci. 2007 Jun;7(2):86-92 [17594285.001]
  • [Cites] Pediatr Infect Dis J. 1997 Feb;16(2):163-79 [9041596.001]
  • [Cites] Pediatr Infect Dis J. 1996 Dec;15(12):1102-6 [8970220.001]
  • [Cites] Clin Pharmacol Ther. 1986 Sep;40(3):281-6 [3017630.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):199-207 [17570106.001]
  • [Cites] Emerg Infect Dis. 2004 Oct;10(10):1713-20 [15504255.001]
  • [Cites] Clin Infect Dis. 2005 Mar 1;40(5):738-44 [15714422.001]
  • [Cites] Ann Intern Med. 1998 Jan 1;128(1):21-8 [9424977.001]
  • [Cites] J Infect Dis. 1985 Nov;152(5):869-75 [2995511.001]
  • [Cites] MMWR Recomm Rep. 1997 Jun 27;46(RR-12):1-46 [9214702.001]
  • [Cites] J Pediatr. 1996 Oct;129(4):488-90 [8859252.001]
  • [Cites] JAMA. 1998 Oct 7;280(13):1161-7 [9777816.001]
  • [Cites] Sex Transm Dis. 2005 Oct;32(10):613-8 [16205302.001]
  • [Cites] AIDS. 1997 Jul 15;11(9):1151-8 [9233463.001]
  • [Cites] Ophthalmology. 1998 Jul;105(7):1259-64 [9663231.001]
  • [Cites] Herpes. 2003 Aug;10(2):32-7 [14577952.001]
  • [Cites] Clin Infect Dis. 1998 Jul;27(1):191-204 [9675476.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] Emerg Infect Dis. 2005 Feb;11(2):330-2 [15752458.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] J Pediatr. 1994 Jun;124(6):853-8 [8201466.001]
  • [Cites] Pediatrics. 1978 Jan;61(1):35-41 [400818.001]
  • [Cites] Pediatrics. 2001 Aug;108(2):223-9 [11483781.001]
  • [Cites] Arch Dis Child. 2007 Aug;92(8):693-6 [17185437.001]
  • [Cites] J Infect Dis. 2007 Jan 1;195(1):30-6 [17152006.001]
  • [Cites] Clin Infect Dis. 1999 Feb;28(2):291-6 [10064246.001]
  • [Cites] J Allergy Clin Immunol. 2004 Apr;113(4):742-6 [15100682.001]
  • [Cites] AIDS. 2007 Aug 20;21(13):1811-5 [17690581.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):182-92 [15609227.001]
  • [Cites] Lancet. 2004 May 29;363(9423):1764-7 [15172774.001]
  • [Cites] J Infect Dis. 1998 Jan;177(1):48-56 [9419169.001]
  • [Cites] J Pediatr. 1997 Feb;130(2):289-92 [9042134.001]
  • [Cites] Pediatr Infect Dis J. 2003 Apr;22(4):371-2 [12690281.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40 Suppl 1:S1-84 [15655768.001]
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1563-8 [10747144.001]
  • [Cites] Diagn Microbiol Infect Dis. 2006 Apr;54(4):283-7 [16466889.001]
  • [Cites] Clin Infect Dis. 2007 Jun 15;44(12):e118-20 [17516391.001]
  • [Cites] Am J Ophthalmol. 1993 Mar 15;115(3):293-8 [8117342.001]
  • [Cites] J Infect Dis. 1999 Dec;180(6):2035-8 [10558965.001]
  • [Cites] Hepatology. 2004 Apr;39(4):1147-71 [15057920.001]
  • [Cites] Infect Dis Clin North Am. 1998 Mar;12(1):137-55 [9494835.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Sex Transm Dis. 2002 Mar;29(3):121-5 [11875372.001]
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):656-9 [17301295.001]
  • [Cites] Chest. 1998 Sep;114(3):933-6 [9743188.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1499-504 [12771419.001]
  • [Cites] Emerg Infect Dis. 2000 Nov-Dec;6(6):646-8 [11076725.001]
  • [Cites] J Infect Dis. 2000 Apr;181(4):1428-34 [10753734.001]
  • [Cites] Hepatology. 1995 Nov;22(5):1387-92 [7590652.001]
  • [Cites] JAMA. 2001 Jun 20;285(23):2995-3002 [11410098.001]
  • [Cites] Curr Opin Neurol. 2004 Jun;17(3):365-70 [15167073.001]
  • [Cites] AIDS Res Ther. 2007 May 08;4:9 [17488505.001]
  • [Cites] Pediatr Radiol. 2003 Jul;33(7):453-60 [12739082.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):382-9 [15368523.001]
  • [Cites] Aust N Z J Med. 2000 Aug;30(4):441-9 [10985508.001]
  • [Cites] Pediatr Infect Dis J. 2006 May;25(5):470 [16645523.001]
  • [Cites] AIDS. 2007 Oct 1;21(15):2059-66 [17885296.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Mar;55(1):122-5 [9332571.001]
  • [Cites] Hepatology. 2000 Mar;31(3):751-5 [10706568.001]
  • [Cites] Int J Tuberc Lung Dis. 2006 Oct;10(10):1091-7 [17044200.001]
  • [Cites] Pediatr Infect Dis J. 1995 Aug;14(8):714-6 [8532434.001]
  • [Cites] Pediatr Infect Dis J. 1997 Apr;16(4):358-63 [9109136.001]
  • [Cites] Pediatr Infect Dis J. 2006 Dec;25(12):1186-8 [17133169.001]
  • [Cites] J Med Virol. 2003 Aug;70(4):600-5 [12794723.001]
  • [Cites] Clin Infect Dis. 1996 Sep;23(3):515-21 [8991477.001]
  • [Cites] HIV Clin Trials. 2000 Jul-Aug;1(1):1-6 [11590483.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1792-8 [12050339.001]
  • [Cites] Obstet Gynecol. 2001 Mar;97(3):443-8 [11239654.001]
  • [Cites] J Clin Microbiol. 1991 Jul;29(7):1323-7 [1715881.001]
  • [Cites] Pediatr Infect Dis J. 2004 Aug;23(8):781-2 [15295232.001]
  • [Cites] Am J Obstet Gynecol. 2007 Oct;197(4):340-5 [17904956.001]
  • [Cites] Clin Infect Dis. 1994 Oct;19(4):741-5 [7803641.001]
  • [Cites] N Engl J Med. 1999 Jul 8;341(2):77-84 [10395631.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):275-80 [16511422.001]
  • [Cites] Pediatr Infect Dis J. 1988 Nov;7(11):799-805 [3068620.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):32-40 [16675537.001]
  • [Cites] J Pediatr. 1992 Nov;121(5 Pt 1):677-83 [1432413.001]
  • [Cites] Clin Infect Dis. 2001 Mar 15;32(6):851-4 [11247707.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1378-85 [11070102.001]
  • [Cites] J Hepatol. 2004 Apr;40(4):653-9 [15030982.001]
  • [Cites] Clin Microbiol Rev. 1996 Jul;9(3):361-81 [8809466.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):95-9 [10619739.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):209-12 [12517850.001]
  • [Cites] J Microbiol Immunol Infect. 2004 Aug;37(4):250-3 [15340655.001]
  • [Cites] Clin Infect Dis. 2003 Mar 15;36(6):789-94 [12627365.001]
  • [Cites] J Clin Gastroenterol. 2007 Jan;41(1):111-4 [17198073.001]
  • [Cites] Sex Transm Dis. 2006 Apr;33(4):259-64 [16452834.001]
  • [Cites] Thorax. 2003 Jul;58(7):594-7 [12832674.001]
  • [Cites] Clin Infect Dis. 1994 Dec;19(6):1165-6 [7888559.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Dec;19(12):1357-62 [15610308.001]
  • [Cites] AIDS. 1997 Oct;11(12):1463-71 [9342068.001]
  • [Cites] Lancet. 2004 Oct 16-22;364(9443):1428-34 [15488218.001]
  • [Cites] Drugs. 2007;67(2):269-98 [17284090.001]
  • [Cites] Obstet Gynecol. 2006 Jul;108(1):141-7 [16816068.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):168-74 [11188837.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e21 [17284154.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jul;23(7):683-5 [15247614.001]
  • [Cites] J Clin Invest. 1998 Jan 15;101(2):497-502 [9435323.001]
  • [Cites] Pediatrics. 1998 Aug;102(2 Pt 1):355-9 [9685438.001]
  • [Cites] Am J Med. 2002 Sep;113(4):294-9 [12361815.001]
  • [Cites] Pediatr Pulmonol. 2003 Jul;36(1):58-62 [12772225.001]
  • [Cites] J Infect Dis. 1993 Sep;168(3):557-63 [8394858.001]
  • [Cites] J Infect Dis. 1998 Apr;177(4):1080-3 [9534987.001]
  • [Cites] Am J Dis Child. 1985 Nov;139(11):1124-33 [4061408.001]
  • [Cites] N Engl J Med. 1993 Jul 1;329(1):8-13 [8505963.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1120-6 [12384847.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:88-92 [12709878.001]
  • [Cites] Pediatr Infect Dis J. 1995 Jun;14(6):455-69; quiz 469-70 [7667049.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1111:336-42 [17363429.001]
  • [Cites] Ann Trop Paediatr. 2001 Mar;21(1):77-80 [11284252.001]
  • [Cites] Expert Rev Anti Infect Ther. 2006 Jun;4(3):469-78 [16771623.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Clin Microbiol Infect. 2004 Nov;10(11):1029-31 [15522012.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):879-80 [15472833.001]
  • [Cites] Pediatr Neurol. 2007 Sep;37(3):186-91 [17765806.001]
  • [Cites] Emerg Infect Dis. 2004 Oct;10(10):1766-73 [15504262.001]
  • [Cites] J Pediatr. 2004 Jan;144(1):100-6 [14722526.001]
  • [Cites] Scand J Infect Dis. 2006;38(8):716-8 [16857624.001]
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):555-9 [9077606.001]
  • [Cites] Sex Transm Dis. 2004 Jan;31(1):57-62 [14695959.001]
  • [Cites] Eur J Paediatr Neurol. 2005;9(6):423-6 [16269259.001]
  • [Cites] Pediatrics. 1994 Jan;93(1):104-8 [8265302.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] AIDS. 1994 Sep;8(9):1281-4 [7802981.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1110-6 [17058225.001]
  • [Cites] Obstet Gynecol. 1999 Apr;93(4):475-9 [10214817.001]
  • [Cites] Pediatr Infect Dis J. 2002 Oct;21(10):981-2 [12400531.001]
  • [Cites] Lancet. 2002 Sep 28;360(9338):985-90 [12383668.001]
  • [Cites] JAMA. 1987 May 15;257(19):2617-21 [3494857.001]
  • [Cites] J Infect Dis. 2006 Jan 1;193(1):9-15 [16323126.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] N Engl J Med. 1992 Jan 9;326(2):83-9 [1727236.001]
  • [Cites] Pediatr Infect Dis J. 1994 Aug;13(8):697-703 [7970969.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1368 [9149705.001]
  • [Cites] MMWR Recomm Rep. 2000 Oct 6;49(RR-9):1-35 [11055835.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1344-54 [17058223.001]
  • [Cites] Pediatr Infect Dis J. 2004 Dec;23(12):1093-7 [15626944.001]
  • [Cites] Clin Infect Dis. 2005 Jan 1;40(1):136-45 [15614703.001]
  • [Cites] Pediatr Infect Dis J. 2001 Jan;20(1):40-8 [11176565.001]
  • [Cites] Int J Tuberc Lung Dis. 2006 Jul;10(7):732-8 [16848333.001]
  • [Cites] Clin Infect Dis. 1994 May;18(5):789-92 [8075272.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Jan;39(1):1-8 [7695288.001]
  • [Cites] J Infect Dis. 2000 Aug;182(2):611-5 [10915098.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 Mar;7(3):254-60 [8106965.001]
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S94-8 [8547519.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1526-9 [9163474.001]
  • [Cites] Pediatr Infect Dis J. 1989 Sep;8(9):586-90 [2797953.001]
  • [Cites] J Trop Pediatr. 2006 Jun;52(3):206-11 [16339160.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1122-31 [12715306.001]
  • [Cites] BJOG. 2001 Apr;108(4):371-7 [11305543.001]
  • [Cites] Pediatr Infect Dis J. 1991 Dec;10(12):888-94 [1766703.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Obstet Gynecol. 1999 Jan;93(1):5-8 [9916946.001]
  • [Cites] Antivir Ther. 2006;11(2):255-61 [16640106.001]
  • [Cites] Pediatr Infect Dis J. 1992 Feb;11(2):127-8 [1741185.001]
  • [Cites] J Pediatr. 1992 Mar;120(3):483-6 [1311378.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1485-9 [15156489.001]
  • [Cites] Arch Pediatr Adolesc Med. 2007 Feb;161(2):125-30 [17283296.001]
  • [Cites] Ocul Immunol Inflamm. 1999 Dec;7(3-4):189-98 [10611727.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Sep;68(1-2):93-6 [8886688.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Jun;35(2):291-314, viii [16880067.001]
  • [Cites] Int J Parasitol. 2000 Jun;30(7):795-804 [10899524.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1998 Nov-Dec;92(6):663-6 [10326116.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):158-63 [8680887.001]
  • [Cites] MMWR Recomm Rep. 1991 Jan 11;40(RR-1):1-7 [1899280.001]
  • [Cites] Clin Infect Dis. 2002 Dec 1;35(11):1414-7 [12439806.001]
  • [Cites] Clin Infect Dis. 2000 Jun;30(6):877-81 [10854363.001]
  • [Cites] J Infect Dis. 1998 Aug;178(2):539-43 [9697739.001]
  • [Cites] Am J Trop Med Hyg. 2005 Sep;73(3):576-82 [16172484.001]
  • [Cites] Pediatrics. 1996 Feb;97(2):198-203 [8584377.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):73-80 [1675763.001]
  • [Cites] Ophthalmology. 2007 Apr;114(4):780-6 [17258320.001]
  • [Cites] Pediatr Infect Dis J. 2005 Apr;24(4):358-64 [15818297.001]
  • [Cites] J Pediatr. 2005 Aug;147(2):227-32 [16126055.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):130-4 [15639294.001]
  • [Cites] Pediatr Infect Dis J. 1999 May;18(5):476-8 [10353529.001]
  • [Cites] Biol Pharm Bull. 2006 Aug;29(8):1706-11 [16880629.001]
  • [Cites] Pediatrics. 2003 Jan;111(1):153-7 [12509569.001]
  • [Cites] AIDS. 1992 Aug;6(8):837-41 [1418781.001]
  • [Cites] Pediatr Infect Dis J. 1998 Oct;17(10):931-3 [9802645.001]
  • [Cites] Intensive Care Med. 1995 Mar;21(3):261-3 [7790617.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2077-87 [15551205.001]
  • [Cites] Am J Ophthalmol. 1998 Dec;126(6):817-22 [9860006.001]
  • [Cites] J Infect Dis. 2000 Feb;181(2):419-24 [10669321.001]
  • [Cites] MMWR Recomm Rep. 1999 Aug 20;48(RR-10):1-59, 61-6 [10499670.001]
  • [Cites] Lancet. 2004 Jun 12;363(9425):1965-76 [15194258.001]
  • [Cites] Pediatr Clin North Am. 2000 Feb;47(1):1-20, v [10697639.001]
  • [Cites] Drug Resist Updat. 2005 Aug;8(4):235-45 [16054422.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):121-6 [6330661.001]
  • [Cites] Transplantation. 2000 Jun 27;69(12):2474-9 [10910264.001]
  • [Cites] Pediatr Infect Dis J. 2000 Feb;19(2):122-8 [10693998.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Aug;29(2):163-70 [10435653.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1567-9 [16847420.001]
  • [Cites] J Infect Dis. 2001 Jul 1;184(1):103-6 [11398117.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):23-33 [8540847.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):62-7 [16274835.001]
  • [Cites] Clin Infect Dis. 1993 Aug;17(2):264-6 [8399879.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):52-7 [8551421.001]
  • [Cites] Pediatr Infect Dis J. 2000 Nov;19(11):1095-6 [11099094.001]
  • [Cites] Clin Infect Dis. 2006 Jun 1;42(11):1639-46 [16652323.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):564-8 [18030234.001]
  • [Cites] Arch Pediatr Adolesc Med. 2004 Oct;158(10):1007-13 [15466691.001]
  • [Cites] Transplantation. 1998 May 27;65(10):1408-11 [9625030.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1898-906 [11919250.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):504-8 [16652060.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jul;158(1):157-61 [9655723.001]
  • [Cites] Pediatr Infect Dis J. 1997 Feb;16(2):222-6 [9041605.001]
  • [Cites] Pediatr Infect Dis J. 2000 Dec;19(12):1141-7 [11144373.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):247-52 [9989893.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):1785-91 [15909267.001]
  • [Cites] S Afr Med J. 2006 Jul;96(7):627-9 [16909188.001]
  • [Cites] Pediatr Pulmonol. 1997 Nov;24(5):370-3 [9407571.001]
  • [Cites] Hepatology. 2000 Feb;31(2):545 [10691379.001]
  • [Cites] Cutis. 1992 Jan;49(1):27-31 [1733656.001]
  • [Cites] BMC Infect Dis. 2007;7:28 [17442100.001]
  • [Cites] AIDS. 1993 Jan;7(1):87-90 [8442922.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3894-9 [16957030.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):e488-94 [15772172.001]
  • [Cites] Pediatrics. 2002 May;109(5):765-71 [11986434.001]
  • [Cites] Obstet Gynecol. 2007 Feb;109(2 Pt 1):403-9 [17267842.001]
  • [Cites] Sex Transm Dis. 2006 Nov;33(11):675-6 [16794558.001]
  • [Cites] Pediatr Infect Dis J. 2000 Jun;19(6):511-6 [10877164.001]
  • [Cites] Pediatr Infect Dis J. 1997 Dec;16(12):1108-12 [9427454.001]
  • [Cites] MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40 [17585291.001]
  • [Cites] Crit Care Med. 2006 Sep;34(9):2370-6 [16849999.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Pediatr Infect Dis J. 1990 Feb;9(2):129-32 [2314952.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):658-61 [10770727.001]
  • [Cites] Br J Ophthalmol. 1994 Feb;78(2):120-4 [8123619.001]
  • [Cites] Am J Epidemiol. 1981 Jan;113(1):12-21 [6257108.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):859-60 [16568443.001]
  • [Cites] Clin Infect Dis. 2000 Mar;30(3):585-6 [10722449.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Pediatr. 2000 Dec;137(6):871-4 [11113846.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4516-7 [16983122.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):825 [7862196.001]
  • [Cites] J Pediatr. 2003 Jul;143(1):4-6 [12915814.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1365-76 [17046469.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):903-5 [11081393.001]
  • [Cites] Clin Infect Dis. 1994 Jan;18(1):38-72 [8054436.001]
  • [Cites] Int J STD AIDS. 2001 Jun;12(6):410-1 [11368827.001]
  • [Cites] Pediatr Infect Dis. 1984 Jul-Aug;3(4):349-57 [6473140.001]
  • [Cites] Clin Infect Dis. 2003 Nov 15;37(10):1340-8 [14583868.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Mar 23;56(11):250-3 [17380107.001]
  • [Cites] Pediatr Infect Dis J. 1996 Jun;15(6):549-51 [8783359.001]
  • [Cites] Infect Control Hosp Epidemiol. 1996 Mar;17(3):170-2 [8708356.001]
  • [Cites] Adv Dent Res. 2006;19(1):57-62 [16672551.001]
  • [Cites] Clin Microbiol Rev. 1997 Jul;10(3):401-18 [9227859.001]
  • [Cites] AIDS. 1995 Oct;9(10):1153-8 [8519451.001]
  • [Cites] Pediatrics. 1999 Jul;104(1 Pt 1):55-60 [10390260.001]
  • [Cites] Pediatr Infect Dis J. 1994 Nov;13(11):963-8 [7845749.001]
  • [Cites] AIDS. 2005 Jul 1;19(10):1043-9 [15958835.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jan;24(1):46-56 [15665710.001]
  • [Cites] Clin Radiol. 2006 May;61(5):393-401 [16679111.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2146-55 [16723577.001]
  • [Cites] J Infect Dis. 2002 Aug 15;186(4):553-7 [12195384.001]
  • [Cites] Pediatr Infect Dis J. 1999 Dec;18(12):1065-8 [10608625.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1445-54 [17409326.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):770-5 [15472806.001]
  • [Cites] J Virol. 1999 Jun;73(6):4786-93 [10233939.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jan;24(1):81-2 [15665715.001]
  • [Cites] Neuropediatrics. 2007 Feb;38(1):32-5 [17607602.001]
  • [Cites] Int J Tuberc Lung Dis. 2004 Jan;8(1):59-69 [14974747.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1383-94 [16619149.001]
  • [Cites] Pediatr Infect Dis J. 1992 Nov;11(11):950-5 [1454438.001]
  • [Cites] MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23 [16708058.001]
  • [Cites] Int J Epidemiol. 2003 Oct;32(5):727-34 [14559740.001]
  • [Cites] J Am Acad Dermatol. 2006 Jul;55(1):47-53 [16781291.001]
  • [Cites] Am J Med. 1995 Apr;98(4):336-42 [7709945.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1996 Feb;15(2):139-45 [8801086.001]
  • [Cites] J Med Virol. 1998 Jan;54(1):12-9 [9443104.001]
  • [Cites] Ann Intern Med. 1995 Dec 1;123(11):845-7 [7486467.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] Am J Ophthalmol. 2000 May;129(5):634-9 [10844056.001]
  • [Cites] J Pediatr Surg. 2007 Mar;42(3):549-52 [17336197.001]
  • [Cites] Pediatr Infect Dis J. 2002 Apr;21(4):291-7 [12075759.001]
  • [Cites] Clin Infect Dis. 1992 Dec;15(6):1031-8 [1457634.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] N Engl J Med. 2001 Mar 1;344(9):637-43 [11228278.001]
  • [Cites] Infect Dis Obstet Gynecol. 2002;10(2):71-7 [12530483.001]
  • [Cites] J Infect Dis. 1999 Jul;180(1):167-75 [10353875.001]
  • [Cites] J Child Neurol. 2006 Sep;21(9):788-94 [16970887.001]
  • [Cites] JAMA. 2007 Feb 21;297(7):724-32 [17312292.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1496-500 [9395360.001]
  • [Cites] Clin Infect Dis. 1998 Mar;26(3):556-65 [9524822.001]
  • [Cites] Ann Intern Med. 1992 Jul 15;117(2):106-11 [1351371.001]
  • [Cites] N Engl J Med. 1991 Mar 7;324(10):654-62 [1994248.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):900-6 [7795092.001]
  • [Cites] N Engl J Med. 1994 Mar 31;330(13):901-5 [8114861.001]
  • [Cites] JAMA. 2002 Mar 13;287(10):1295-300 [11886321.001]
  • [Cites] J Infect Dis. 2004 Oct 15;190(8):1413-21 [15378433.001]
  • [Cites] Clin Infect Dis. 1998 Dec;27(6):1510-3 [9868668.001]
  • [Cites] Clin Eye Vis Care. 2000 Dec;12(3-4):119-129 [11137426.001]
  • [Cites] Arch Ophthalmol. 2003 Apr;121(4):466-76 [12695243.001]
  • [Cites] J Med Virol. 2007 Aug;79(8):1194-8 [17596822.001]
  • [Cites] Clin Infect Dis. 2000 Jul;31(1):170-6 [10913417.001]
  • [Cites] N Engl J Med. 1997 Oct 16;337(16):1105-11 [9329932.001]
  • [Cites] Arch Med Res. 2000 Nov-Dec;31(6):592-8 [11257327.001]
  • [Cites] Pediatr Infect Dis J. 2006 Oct;25(10):948-50 [17006296.001]
  • [Cites] Clin Infect Dis. 2002 Sep 15;35(6):769-72 [12203177.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):325-9 [8070441.001]
  • [Cites] Pediatrics. 2007 Apr;119(4):772-84 [17403849.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):35-40 [1310201.001]
  • [Cites] MMWR Recomm Rep. 2005 May 27;54(RR-7):1-21 [15917737.001]
  • [Cites] J Med Virol. 2000 Jun;61(2):208-13 [10797376.001]
  • [Cites] J Antimicrob Chemother. 2004 Jul;54(1):292-4 [15190025.001]
  • [Cites] N Engl J Med. 1992 May 28;326(22):1445-50 [1315416.001]
  • [Cites] Pediatr Infect Dis J. 1997 Dec;16(12):1162-5 [9427463.001]
  • [Cites] Clin Infect Dis. 2001 Mar 15;32(6):855-61 [11247708.001]
  • [Cites] Curr Opin Pediatr. 2000 Jun;12(3):269-74 [10836165.001]
  • [Cites] Pediatr Infect Dis J. 2001 Dec;20(12):1132-5 [11740319.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51 [16950017.001]
  • [Cites] MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60 [18685555.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):253-8 [7959293.001]
  • [Cites] Ophthalmology. 2005 Nov;112(11):1876-82 [16171866.001]
  • [Cites] Clin Infect Dis. 2007 May 1;44(9):1143-9 [17407029.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):431-4 [3997072.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):159-67 [11172138.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1331-8 [17005950.001]
  • [Cites] Hepatology. 2006 Mar;43(3):556-62 [16496323.001]
  • [Cites] MMWR Recomm Rep. 2006 Aug 4;55(RR-11):1-94 [16888612.001]
  • [Cites] J Infect Dis. 1998 Sep;178(3):904-7 [9728570.001]
  • [Cites] J Pediatr. 2006 Feb;148(2):228-233 [16492434.001]
  • [Cites] Pediatrics. 2001 Aug;108(2):230-8 [11483782.001]
  • [Cites] Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87 [16894075.001]
  • [Cites] J Infect. 2006 Nov;53(5):337-49 [16678903.001]
  • [Cites] Arch Pediatr Adolesc Med. 2006 Sep;160(9):937-42 [16953017.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1375-80 [12423984.001]
  • [Cites] AIDS Patient Care STDS. 1996 Dec;10(6):336-41 [11361548.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1791-7 [12218391.001]
  • [Cites] J Antimicrob Chemother. 2005 Oct;56(4):745-55 [16135526.001]
  • [Cites] Pediatr Infect Dis J. 1998 Jun;17(6):447-52 [9655532.001]
  • [Cites] Ann Intern Med. 1983 Jun;98(6):958-72 [6344712.001]
  • [Cites] Arch Intern Med. 2004 Feb 23;164(4):454-8 [14980998.001]
  • [Cites] MMWR Recomm Rep. 2000 May 9;49(RR-5):1-22; quiz CE1-7 [15580728.001]
  • [Cites] Am J Dis Child. 1993 Mar;147(3):320-4 [8094939.001]
  • [Cites] AIDS Patient Care STDS. 2000 Dec;14(12):651-7 [11119432.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jul;25(7):648-9 [16804439.001]
  • [Cites] Pediatr Infect Dis J. 1997 Apr;16(4):417-8 [9109150.001]
  • [Cites] Lancet. 2000 Sep 23;356(9235):1051-6 [11009139.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):70-80 [15653819.001]
  • [Cites] Pediatr Infect Dis J. 1999 Aug;18(8):694-7 [10462338.001]
  • [Cites] J Infect Dis. 2004 Jan 1;189(1):46-50 [14702152.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jan;196(1):43.e1-6 [17240228.001]
  • [Cites] Pediatr Pulmonol. 2001 Apr;31(4):267-76 [11288208.001]
  • [Cites] Clin Infect Dis. 2004 Feb 15;38(4):565-71 [14765351.001]
  • [Cites] AIDS. 1993 Apr;7(4):507-12 [8099487.001]
  • [Cites] Transplantation. 2006 Feb 15;81(3):320-6 [16477215.001]
  • [Cites] Pediatr Infect Dis J. 2003 Jul;22(7):593-8 [12867833.001]
  • [Cites] Int J Tuberc Lung Dis. 2005 Jul;9(7):716-26 [16013765.001]
  • [Cites] J Infect Dis. 2003 Oct 1;188(7):954-9 [14513413.001]
  • [Cites] Infection. 2007 Jun;35(3):175-9 [17565459.001]
  • [Cites] Clin Infect Dis. 2007 Feb 1;44(3):373-9 [17205443.001]
  • [Cites] AIDS. 1992 Dec;6(12):1557-8 [1492948.001]
  • [Cites] MMWR Recomm Rep. 2005 Dec 23;54(RR-16):1-31 [16371945.001]
  • [Cites] Am J Obstet Gynecol. 1988 May;158(5):1189-95 [2835906.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1341-8 [14523142.001]
  • [Cites] J Infect Dis. 1999 Jul;180(1):50-5 [10353860.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Mar;51(3):812-8 [17210771.001]
  • [Cites] Obstet Gynecol. 1996 Mar;87(3):338-44 [8598951.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416 [17277290.001]
  • [Cites] Scand J Infect Dis. 2007;39(2):146-51 [17366032.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] Clin Infect Dis. 1998 Oct;27(4):796-806 [9798036.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2005 Mar;90(2):F156-60 [15724041.001]
  • [Cites] AIDS. 2007 Nov 30;21(18):2534-6 [18025892.001]
  • [Cites] J Pediatr. 1984 Oct;105(4):569-75 [6090628.001]
  • [Cites] Pediatr Infect Dis J. 2002 Mar;21(3):240-8 [12005089.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1207-21 [17049017.001]
  • [Cites] Am J Med. 1988 Aug;85(2):203-6 [3165248.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):901-11 [10554799.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Feb;50(2):632-8 [16436720.001]
  • [Cites] Lancet. 1990 May 12;335(8698):1166 [1971901.001]
  • [Cites] Clin Infect Dis. 2003 Jul 1;37(1):82-7 [12830412.001]
  • [Cites] Clin Infect Dis. 2001 Jun 1;32(11):1608-14 [11340533.001]
  • [Cites] AIDS. 2000 Mar 10;14(4):383-6 [10770540.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72 [15155217.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):77-82 [11305476.001]
  • [Cites] J Infect Dis. 1998 Oct;178(4):1047-52 [9806033.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):45-51 [15937762.001]
  • [Cites] Pediatrics. 2000 Apr;105(4 Pt 1):836-42 [10742329.001]
  • [Cites] J Pediatr Endocrinol Metab. 2007 Feb;20(2):237-45 [17396441.001]
  • [Cites] Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26 [17143845.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2889-93 [11153670.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1080-6 [9129069.001]
  • [Cites] Pediatr Infect Dis J. 2005 Aug;24(8):700-4 [16094224.001]
  • [Cites] DNA Cell Biol. 2003 Jun;22(6):431-40 [12906736.001]
  • [Cites] MMWR Surveill Summ. 2007 Jun 8;56(6):23-40 [17557074.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3768-71 [11574614.001]
  • [Cites] BMJ. 2007 Jan 20;334(7585):136 [17085459.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3097-101 [10488160.001]
  • [Cites] J Infect Dis. 2003 May 1;187(9):1469-74 [12717629.001]
  • [Cites] N Engl J Med. 1994 Jun 30;330(26):1858-63 [7818637.001]
  • [Cites] Hepatology. 2005 May;41(5):1013-8 [15793840.001]
  • [Cites] Transpl Infect Dis. 2006 Sep;8(3):128-39 [16913971.001]
  • [Cites] Clin Infect Dis. 2007 Feb 15;44(4):607-14 [17243069.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1643-51 [10823764.001]
  • [Cites] J Pediatr. 1998 Feb;132(2):285-90 [9506642.001]
  • [Cites] Chemotherapy. 1996 Jul-Aug;42(4):308-14 [8804799.001]
  • [Cites] Pediatr Infect Dis J. 1998 May;17(5):381-5 [9613650.001]
  • [Cites] Ann Neurol. 1993 Jun;33(6):597-603 [8388679.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Dec;6(12):1311-6 [8254467.001]
  • [Cites] AIDS. 2001 Jan 5;15(1):23-31 [11192865.001]
  • [Cites] AIDS. 2007 Jan 2;21(1):77-84 [17148971.001]
  • [Cites] J Infect Dis. 2008 Jan 15;197(2):279-82 [18179386.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):745-53 [16842569.001]
  • [Cites] N Engl J Med. 1980 May 8;302(19):1073-6 [6245360.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):494-8 [17033525.001]
  • [Cites] J Infect. 1996 Jul;33(1):23-32 [8842991.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Clin Virol. 2000 May;16(3):149-57 [10738135.001]
  • [Cites] J Infect Dis. 1996 Apr;173(4):870-6 [8603965.001]
  • [Cites] Arch Dis Child. 2003 Dec;88(12):1112-8 [14670782.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jun;81(6):867-72 [17392728.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Nov;49(11):4536-45 [16251293.001]
  • [Cites] JAMA. 2003 Jan 8;289(2):203-9 [12517231.001]
  • [Cites] Pediatr Pulmonol. 2001 Mar;31(3):205-13 [11276133.001]
  • [Cites] Clin Infect Dis. 2001 Aug 1;33(3):393-8 [11438910.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:25-31 [12709868.001]
  • [Cites] N Engl J Med. 2005 Jan 6;352(1):39-47 [15635111.001]
  • [Cites] Obstet Gynecol. 1998 Jan;91(1):92-6 [9464728.001]
  • [Cites] Arch Intern Med. 1996 Feb 12;156(3):321-5 [8572843.001]
  • [Cites] Clin Infect Dis. 2002 Feb 1;34(3):371-8 [11774085.001]
  • [Cites] J Pediatr. 2007 Oct;151(4):374-7 [17889072.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):105-9 [2052043.001]
  • [Cites] MMWR Recomm Rep. 2009 Feb 6;58(RR-2):1-25 [19194371.001]
  • [Cites] J Antimicrob Chemother. 2002 Feb;49 Suppl 1:11-9 [11801576.001]
  • [Cites] N Engl J Med. 1994 Nov 3;331(18):1181-7 [7935655.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2346-7 [17554115.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2321-9 [17117018.001]
  • [Cites] Pediatrics. 2000 Oct;106(4):E53 [11015548.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):189-92 [10188717.001]
  • [Cites] Clin Infect Dis. 2003 Feb 1;36(3):275-80 [12539067.001]
  • [Cites] Chest. 2001 Jul;120(1):193-7 [11451837.001]
  • [Cites] J Infect Dis. 1996 Jun;173(6):1477-80 [8648224.001]
  • [Cites] N Engl J Med. 1997 Jul 3;337(1):15-21 [9203426.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):335-9 [11273213.001]
  • [Cites] J Adolesc Health. 2001 Sep;29(3 Suppl):49-56 [11530303.001]
  • [Cites] Clin Infect Dis. 2002 Mar 1;34(5):641-8 [11803508.001]
  • [Cites] J Infect Dis. 1985 Aug;152(2):243-8 [2993429.001]
  • [Cites] Pediatr Infect Dis J. 2007 Aug;26(8):755-7 [17848894.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):615-20 [7637721.001]
  • [Cites] Antiviral Res. 2004 Oct;64(1):17-25 [15451175.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):976-82 [12975271.001]
  • [Cites] JAMA. 2003 Feb 26;289(8):1008-11 [12597753.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1204-7 [9195083.001]
  • [Cites] Pediatrics. 2004 Aug;114(2):333-41 [15286213.001]
  • [Cites] J Med Virol. 2002 Jun;67(2):137-42 [11992574.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1280-4 [12395341.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):81-3 [17554705.001]
  • [Cites] J Infect Dis. 1993 Dec;168(6):1562-5 [8245547.001]
  • [Cites] Pediatr Infect Dis J. 2000 Jan;19(1):52-6 [10643851.001]
  • [Cites] J Infect Dis. 2004 Aug 15;190(4):693-6 [15272395.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Jan;44(1):92-8 [17204960.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1644-7 [11980934.001]
  • [Cites] J Infect Dis. 2005 Dec 1;192(11):1880-9 [16267758.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):164-5 [8036659.001]
  • [Cites] Am J Obstet Gynecol. 1999 May;180(5):1110-4 [10329863.001]
  • [Cites] Intervirology. 1998;41(4-5):208-12 [10213898.001]
  • [Cites] Pediatr Infect Dis J. 1991 Feb;10(2):130-3 [2062604.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Aug 10;56(31):794-5 [17694617.001]
  • [Cites] Clin Infect Dis. 1993 Sep;17(3):480-3 [8218693.001]
  • [Cites] Clin Liver Dis. 2006 Feb;10(1):133-48, vii [16376798.001]
  • [Cites] J Pediatr. 1992 Oct;121(4):574-8 [1403392.001]
  • [Cites] Clin Infect Dis. 2001 Dec 1;33(11):1910-3 [11692303.001]
  • [Cites] Arch Med Res. 2005 Jan-Feb;36(1):24-31 [15777991.001]
  • [Cites] Semin Perinatol. 2007 Feb;31(1):19-25 [17317423.001]
  • [Cites] Pediatr Infect Dis J. 1994 Sep;13(9):801-5 [7808850.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 Jul-Aug;17(4):569-76 [9211549.001]
  • [Cites] J Infect Dis. 2002 Feb 15;185 Suppl 1:S73-82 [11865443.001]
  • [Cites] J Clin Microbiol. 1995 Jul;33(7):1968-70 [7665687.001]
  • [Cites] Pediatrics. 1992 May;89(5 Pt 1):891-4 [1315949.001]
  • [Cites] Clin Infect Dis. 2001 Aug 15;33(4):562-9 [11462196.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Aug 13;53(31):716-9 [15306757.001]
  • [Cites] Ophthalmology. 1994 Jul;101(7):1250-61 [8035989.001]
  • [Cites] Medicine (Baltimore). 1993 Mar;72(2):67-77 [8386795.001]
  • [Cites] Pediatr Infect Dis J. 1997 Jan;16(1):84 [9002113.001]
  • [Cites] J Clin Microbiol. 2001 Jun;39(6):2267-71 [11376068.001]
  • [Cites] Arch Pediatr Adolesc Med. 2000 Feb;154(2):127-34 [10665598.001]
  • [Cites] Int J Infect Dis. 2001;5(3):119-25 [11724667.001]
  • [Cites] Pediatr Radiol. 1988;18(2):118-22 [3281109.001]
  • [Cites] Sex Transm Dis. 2007 Sep;34(9):704-8 [17413535.001]
  • [Cites] Pediatr Infect Dis J. 1993 Jun;12(6):499-504 [7688450.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1139-44 [10091799.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):948-55 [11035345.001]
  • [Cites] Clin Infect Dis. 2006 Feb 1;42(3):418-27 [16392092.001]
  • [Cites] J Clin Gastroenterol. 2005 Jan;39(1):68-70 [15599215.001]
  • [Cites] N Engl J Med. 1977 Dec 29;297(26):1419-26 [412099.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):124-9 [11103042.001]
  • [Cites] Acta Gastroenterol Belg. 1998 Apr-Jun;61(2):219-23 [9658614.001]
  • [Cites] Pediatr Infect Dis J. 1996 Sep;15(9):796-800 [8878224.001]
  • [Cites] J Infect Dis. 2005 Dec 1;192(11):1872-9 [16267757.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2341 [15155250.001]
  • [Cites] Lancet. 2000 Sep 23;356(9235):1062-5 [11009141.001]
  • [Cites] Clin Microbiol Infect. 2006 Jul;12(7):666-71 [16774564.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):1921-33 [15155180.001]
  • [Cites] Ann Intern Med. 1992 Jan 1;116(1):33-43 [1727093.001]
  • [Cites] Clin Infect Dis. 1997 Nov;25(5):1165-72 [9402377.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jul;25(7):645-8 [16804438.001]
  • [Cites] Pediatrics. 1993 Jul;92(1):83-5 [8516089.001]
  • [Cites] Ann Trop Paediatr. 1996 Dec;16(4):361-8 [8985536.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1182-7 [9593001.001]
  • [Cites] Pediatr Infect Dis J. 1996 Mar;15(3):247-54 [8852914.001]
  • [Cites] Pediatrics. 2007 Jul;120(1):100-9 [17606567.001]
  • [Cites] Clin Infect Dis. 1999 Feb;28(2):314-21 [10064250.001]
  • [Cites] J Infect Dis. 1986 Mar;153(3):634-7 [2936830.001]
  • [Cites] Pediatr Infect Dis J. 2003 Apr;22(4):329-35 [12690272.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Jul;41(7):1541-6 [9210681.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1625-31 [1435899.001]
  • [Cites] Int J Epidemiol. 1998 Feb;27(1):108-17 [9563703.001]
  • [Cites] Pediatr Infect Dis J. 1997 Feb;16(2):216-21 [9041604.001]
  • [Cites] J Med Virol. 2000 Mar;60(3):290-3 [10630961.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):653-7 [10770726.001]
  • [Cites] J Clin Microbiol. 1996 Aug;34(8):1952-6 [8818889.001]
  • [Cites] MMWR Surveill Summ. 2006 May 26;55(4):23-37 [16723971.001]
  • [Cites] N Engl J Med. 1962 Aug 23;267:369-76 [14494142.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):916-23 [11115716.001]
  • [Cites] Eur J Pediatr. 2002 Nov;161(11):563-74 [12424579.001]
  • [Cites] Pharmacotherapy. 1993 Nov-Dec;13(6):640-6 [8302691.001]
  • [Cites] MMWR Recomm Rep. 1995 Jul 14;44(RR-8):1-34 [7565547.001]
  • [Cites] Am J Trop Med Hyg. 2003 Jun;68(6):710-5 [12887032.001]
  • [Cites] Pediatr Infect Dis J. 1992 Jun;11(6):501-2 [1608693.001]
  • [Cites] AIDS. 2006 Sep 11;20(14):1869-77 [16954728.001]
  • [Cites] PLoS Med. 2006 Jun;3(6):e197 [16752952.001]
  • [Cites] Clin Infect Dis. 2005 Nov 1;41(9):1217-23 [16206093.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Jun 29;56(25):625-8 [17597693.001]
  • [Cites] Clin Infect Dis. 2003 Aug 15;37(4):559-66 [12905141.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24 [16048942.001]
  • [Cites] Ann Intern Med. 2000 Nov 7;133(9):676-86 [11074900.001]
  • [Cites] AIDS. 2007 May 31;21(9):1073-89 [17502718.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):e74-7 [15472837.001]
  • [Cites] J Pediatr. 1998 Jan;132(1):169-71 [9470024.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5 [9564455.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):472-7 [15480369.001]
  • [Cites] J Infect Dis. 2006 Sep 1;194(5):633-41 [16897662.001]
  • [Cites] Ann Intern Med. 1991 Nov 1;115(9):665-73 [1656826.001]
  • [Cites] Clin Infect Dis. 1996 Sep;23(3):577-84 [8879783.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):1770-6 [15909265.001]
  • [Cites] Clin Infect Dis. 1995 Nov;21(5):1175-81 [8589139.001]
  • [Cites] J Med Virol. 2003 Jul;70(3):373-7 [12766999.001]
  • [Cites] Diagn Microbiol Infect Dis. 1999 Jun;34(2):147-52 [10354865.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):173-80 [10708288.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):167-8 [10602740.001]
  • [Cites] Cell. 2004 Dec 29;119(7):915-26 [15620351.001]
  • [Cites] Eur J Neurol. 2004 May;11(5):297-304 [15142222.001]
  • [Cites] Lancet. 1999 Jan 16;353(9148):201-3 [9923876.001]
  • [Cites] Obstet Gynecol. 1993 Jul;82(1):102-4 [8390630.001]
  • [Cites] Am J Dis Child. 1992 Jun;146(6):694-9 [1317670.001]
  • [Cites] Clin Infect Dis. 2003 May 15;36(10):1329-31 [12746781.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1301-6 [10219064.001]
  • [Cites] Curr Opin Infect Dis. 2005 Jun;18(3):261-6 [15864105.001]
  • [Cites] Clin Infect Dis. 2007 Oct 1;45(7):807-25 [17806045.001]
  • [Cites] Semin Respir Infect. 2002 Mar;17(1):33-46 [11891517.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):429-37 [11832532.001]
  • [Cites] Pediatrics. 2007 Mar;119(3):e694-704 [17296782.001]
  • [Cites] Pediatr Infect Dis J. 1997 Sep;16(9):876-81 [9306483.001]
  • [Cites] Arch Med Res. 2007 Aug;38(6):702-10 [17613361.001]
  • [Cites] N Engl J Med. 1983 Jun 16;308(24):1448-53 [6343861.001]
  • [Cites] J Neurovirol. 2002 Jun;8(3):158-67 [12053271.001]
  • [Cites] Pediatrics. 2001 Aug;108(2):E39 [11483849.001]
  • [Cites] Pediatr Infect Dis J. 2006 Dec;25(12):1110-5 [17133155.001]
  • [Cites] J Infect Dis. 1982 Jun;145(6):842-8 [6979590.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1525-9 [9834281.001]
  • [Cites] Arch Pathol Lab Med. 2007 May;131(5):702-7 [17488155.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):768-76 [15728809.001]
  • [Cites] Pediatr Clin North Am. 2000 Feb;47(1):79-108 [10697643.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):468-70 [16652055.001]
  • [Cites] Bone Marrow Transplant. 2006 Dec;38(11):769-70 [17013421.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1635-42 [10823763.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Mar 15;51(10):214-5 [11922192.001]
  • [Cites] J Trop Pediatr. 2003 Dec;49(6):384-5 [14725420.001]
  • [Cites] Vaccine. 2006 Apr 12;24(16):3095-9 [16488516.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1202-7 [9367458.001]
  • [Cites] Clin Infect Dis. 2005 Nov 15;41(10):1473-80 [16231260.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1445-57 [12766841.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):200-3 [8567117.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Mar 23;56(11):245-50 [17380106.001]
  • [Cites] Clin Infect Dis. 2006 Jan 1;42(1):8-13 [16323085.001]
  • [Cites] Arch Pediatr Adolesc Med. 1994 Jun;148(6):638-41 [8193693.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):662-78 [10770728.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):1040-3 [7795047.001]
  • [Cites] Eur J Pediatr. 2007 Mar;166(3):195-9 [16944240.001]
  • [Cites] Am J Ophthalmol. 2001 Apr;131(4):457-67 [11292409.001]
  • [Cites] Neuropediatrics. 2001 Oct;32(5):250-5 [11748496.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1055-60 [8922802.001]
  • [Cites] Gut. 2005 Jun;54(6):852-7 [15888796.001]
  • [Cites] Pediatr Infect Dis J. 2002 Jan;21(1):54-6 [11791100.001]
  • [Cites] J Pediatr. 1998 Feb;132(2):277-84 [9506641.001]
  • [Cites] Int J Tuberc Lung Dis. 1998 Oct;2(10):844-51 [9783533.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Sep;41(9):1944-8 [9303390.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003940 [16856025.001]
  • [Cites] Pharmacotherapy. 1999 Nov;19(11):1261-8 [10555932.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):693-9 [7854375.001]
  • [Cites] Pediatr Infect Dis J. 2003 Apr;22(4):384-6 [12712978.001]
  • [Cites] Pediatr Radiol. 1993;23(3):177-80 [8332402.001]
  • [Cites] Clin Infect Dis. 2006 Aug 1;43(3):347-56 [16804851.001]
  • [Cites] Curr Opin Pediatr. 2001 Feb;13(1):56-9 [11176245.001]
  • [Cites] N Engl J Med. 1998 May 7;338(19):1345-51 [9571254.001]
  • [Cites] Scand J Infect Dis. 1987;19(3):347-51 [3303306.001]
  • [Cites] J Pediatr. 2006 Oct;149(4):480-5 [17011318.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1049-52 [16142674.001]
  • [Cites] Eur J Pediatr. 1999 Mar;158(3):187-99 [10094436.001]
  • [Cites] Clin Infect Dis. 1999 Mar;28(3):562-8 [10194079.001]
  • [Cites] Lancet. 2004 Nov 20-26;364(9448):1865-71 [15555666.001]
  • [Cites] Transpl Infect Dis. 2002 Mar;4(1):10-6 [12123421.001]
  • [Cites] J Pediatr. 2007 Feb;150(2):168-74, 174.e1 [17236895.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003650 [16235333.001]
  • [Cites] N Engl J Med. 2001 Nov 22;345(21):1522-8 [11794218.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):337-43 [11015150.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):47-54 [10619732.001]
  • [Cites] Scand J Infect Dis. 2007;39(4):347-50 [17454900.001]
  • [Cites] JAMA. 1986 Oct 10;256(14):1904-8 [3020264.001]
  • [Cites] Arch Virol. 1997;142(3):453-7 [9349291.001]
  • [Cites] Pediatr Infect Dis J. 1991 Sep;10(9):658-62 [1923678.001]
  • [Cites] AIDS. 1998 May 28;12(8):885-93 [9631142.001]
  • [Cites] Pediatrics. 1993 Dec;92(6):838-42 [7901834.001]
  • [Cites] Am J Med. 1993 Mar;94(3):235-40 [8095771.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] J Med Virol. 2002 Aug;67(4):583-8 [12116008.001]
  • [Cites] Pediatr Clin North Am. 2005 Jun;52(3):895-915, viii [15925667.001]
  • [Cites] JAMA. 1998 Feb 4;279(5):384-6 [9459473.001]
  • [Cites] Pediatr Infect Dis J. 2002 May;21(5):388-92 [12150174.001]
  • [Cites] Semin Respir Infect. 2001 Dec;16(4):257-62 [11740827.001]
  • [Cites] Semin Pediatr Infect Dis. 2005 Oct;16(4):271-81 [16210107.001]
  • [Cites] J Child Neurol. 2004 Jan;19(1):35-8 [15032381.001]
  • [Cites] Ophthalmology. 1994 Sep;101(9):1488-502 [8090452.001]
  • [Cites] Am J Dis Child. 1993 Jan;147(1):30-4 [8093422.001]
  • [Cites] Acta Virol. 2007;51(1):13-20 [17432939.001]
  • [Cites] Pediatr Infect Dis J. 2000 Aug;19(8):700-6 [10959736.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):740-1 [11267990.001]
  • [Cites] Clin Infect Dis. 2005 Dec 1;41(11):1654-61 [16267740.001]
  • [Cites] Pediatrics. 1993 Aug;92(2):219-22 [8393173.001]
  • [Cites] Can J Public Health. 2004 Jul-Aug;95(4):245-8 [15362463.001]
  • [Cites] Curr Opin Infect Dis. 2007 Oct;20(5):482-8 [17762781.001]
  • [Cites] Infect Dis Clin North Am. 2005 Sep;19(3):691-711 [16102656.001]
  • [Cites] J Clin Virol. 2006 Feb;35(2):226-31 [16386462.001]
  • [Cites] AIDS. 1999 Sep 10;13(13):1647-51 [10509565.001]
  • [Cites] Ann Intern Med. 1986 Jul;105(1):45-8 [2940954.001]
  • [Cites] Pediatr Infect Dis J. 2001 Jul;20(7):715-6 [11465848.001]
  • [Cites] MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48 [17136024.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):19-23 [7494565.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61 [16950018.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1049-52 [15825000.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):710-8 [10770733.001]
  • [Cites] Int J Infect Dis. 2006 Jul;10(4):282-5 [16460981.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2694-700 [15184454.001]
  • [Cites] MMWR Recomm Rep. 2002 Jun 14;51(RR-8):1-52 [12081007.001]
  • [Cites] Eur J Neurol. 2007 Apr;14(4):418-23 [17388991.001]
  • [Cites] JAMA. 2006 Jul 19;296(3):292-300 [16849662.001]
  • [Cites] Clin Infect Dis. 2002 Jun 15;34(12):1660-2 [12032910.001]
  • [Cites] Pediatr Infect Dis J. 1996 May;15(5):443-7 [8724068.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Mar;22(3):283-8 [16545015.001]
  • [Cites] MMWR Recomm Rep. 1991 Mar 15;40(RR-2):1-13 [1672036.001]
  • [Cites] Arch Dermatol. 1998 Sep;134(9):1169-70 [9762047.001]
  • [Cites] Clin Pediatr (Phila). 2003 Nov-Dec;42(9):763-73 [14686548.001]
  • [Cites] Transplantation. 2002 Feb 27;73(4):661-2 [11889450.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] AIDS. 1996 Oct;10(12):1369-76 [8902066.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1010-8 [16250032.001]
  • [Cites] BMC Infect Dis. 2007;7:30 [17442105.001]
  • [Cites] J Clin Microbiol. 1999 Dec;37(12):4045-7 [10565929.001]
  • [Cites] J Infect Dis. 1994 Aug;170(2):419-24 [8035029.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):414-20 [9237706.001]
  • [Cites] AIDS. 1996 Sep;10(10):1127-33 [8874630.001]
  • [Cites] J Clin Virol. 2007 Mar;38(3):254-9 [17280866.001]
  • [Cites] Pediatr Infect Dis J. 2000 Jun;19(6):576-8 [10877180.001]
  • [Cites] Gynecol Oncol. 1994 Aug;54(2):152-8 [8063239.001]
  • [Cites] Epidemiol Infect. 2001 Jun;126(3):389-96 [11467796.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):629-37 [15468435.001]
  • [Cites] Am J Epidemiol. 2001 Aug 15;154(4):357-65 [11495859.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Rev Med Virol. 2001 Nov-Dec;11(6):381-95 [11747000.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2682-95 [15987917.001]
  • [Cites] Proc Soc Exp Biol Med. 1971 Sep;137(4):1401-4 [5316452.001]
  • [Cites] N Engl J Med. 2007 Jun 21;356(25):2614-21 [17582071.001]
  • [Cites] Pediatr Infect Dis J. 1987 Jun;6(6):532-5 [3615068.001]
  • [Cites] Support Care Cancer. 2003 Nov;11(11):722-7 [13680324.001]
  • [Cites] Sex Transm Dis. 2002 Aug;29(8):427-35 [12172526.001]
  • [Cites] Lancet Infect Dis. 2006 Feb;6(2):83-90 [16439328.001]
  • [Cites] AIDS. 2004 Jun 18;18(9):1342-4 [15362670.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):904-7 [11036896.001]
  • [Cites] J Neurovirol. 2001 Aug;7(4):353-7 [11517416.001]
  • [Cites] Chest. 2003 Nov;124(5):1820-3 [14605054.001]
  • [Cites] N Engl J Med. 1998 Dec 24;339(26):1889-95 [9862944.001]
  • [Cites] MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39 [9790221.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):23-6 [15040533.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Jun 24;54(24):605-8 [15973241.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):131-7 [8816142.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):1084-92 [11049793.001]
  • [Cites] J Clin Microbiol. 2005 May;43(5):2163-7 [15872236.001]
  • [Cites] J Infect Dis. 2005 Sep 15;192(6):984-91 [16107950.001]
  • [Cites] MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57 [9639369.001]
  • [Cites] Intensive Care Med. 1996 Jun;22(6):611-2 [8814483.001]
  • [Cites] Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25 [10511517.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):104-21 [14679456.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):305-10 [8554225.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jan;25(1):53-8 [16395104.001]
  • [Cites] J Virol. 1991 Jun;65(6):2895-902 [1851861.001]
  • [Cites] Clin Infect Dis. 2001 Sep 15;33(6):829-33 [11512088.001]
  • [Cites] Ann Intern Med. 1995 Dec 15;123(12):937-40 [7486489.001]
  • [Cites] Pediatr Infect Dis J. 1999 Aug;18(8):702-8 [10462340.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:68-79 [11525221.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1206-17 [15371578.001]
  • [Cites] J Travel Med. 2003 Jul-Aug;10(4):225-40 [12946301.001]
  • [Cites] Clin Infect Dis. 2005 Mar 15;40(6):890-3 [15736026.001]
  • [Cites] Pediatr Infect Dis J. 1996 Apr;15(4):310-4 [8866799.001]
  • [Cites] Wkly Epidemiol Rec. 2007 May 25;82(21):193-6 [17526121.001]
  • [Cites] Pediatr Infect Dis J. 1997 Nov;16(11):1028-31 [9384334.001]
  • [Cites] Pediatr Infect Dis J. 1995 Feb;14(2):152-4 [7746701.001]
  • [Cites] Clin Infect Dis. 2005 Mar 15;40(6):844-52 [15736018.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89 [16950021.001]
  • [Cites] Am J Med. 2004 Jun 15;116(12):829-34 [15178498.001]
  • [Cites] Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12 [16626917.001]
  • [Cites] J Infect. 2005 Dec;51(5):e289-97 [16321643.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD004932 [17253532.001]
  • [Cites] JAMA. 1994 Feb 16;271(7):531-5 [8301768.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1373-7 [9593027.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Am J Med Sci. 2004 Jul;328(1):57-63 [15254442.001]
  • [Cites] Arch Intern Med. 1993 Nov 8;153(21):2496-8 [7832818.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):797-802 [15472810.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1404-10 [9709750.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1059; author reply 1059-60 [16511783.001]
  • [Cites] J Pediatr. 1994 Feb;124(2):271-3 [8301436.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):2020-9 [12490683.001]
  • [Cites] Am J Med. 1992 Feb;92(2):153-60 [1543199.001]
  • [Cites] Clin Infect Dis. 2002 Nov 15;35(10):1250-7 [12410486.001]
  • [Cites] Pediatr Infect Dis J. 1998 Oct;17(10):872-80 [9802627.001]
  • [Cites] Lancet. 1998 Jan 24;351(9098):252-5 [9457095.001]
  • [Cites] Medicine (Baltimore). 2004 May;83(3):149-75 [15118543.001]
  • [Cites] Ann Intern Med. 1997 Feb 15;126(4):264-74 [9036798.001]
  • [Cites] Sex Transm Dis. 2000 Jan;27(1):53-9 [10654870.001]
  • [Cites] Pediatr Infect Dis J. 2001 Jan;20(1):10-4 [11176560.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Nov;43(11):2586-91 [10543733.001]
  • [Cites] Leukemia. 2008 Mar;22(3):496-503 [18094720.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2004 Sep;98(9):544-52 [15251404.001]
  • [Cites] Am J Med. 1992 Nov;93(5):489-97 [1332471.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Oct 1;37 Suppl 2:S88-94 [15385904.001]
  • [Cites] MMWR Recomm Rep. 1997 Mar 28;46(RR-7):1-25 [9091780.001]
  • [Cites] Pediatr Infect Dis J. 2005 Oct;24(10):921-2 [16220093.001]
  • [Cites] Sex Transm Dis. 2001 Jun;28(6):315-20 [11403187.001]
  • [Cites] J Trop Pediatr. 2005 Dec;51(6):380-2 [15927949.001]
  • [Cites] J Viral Hepat. 2001 Mar;8(2):139-47 [11264734.001]
  • [Cites] Am J Med. 1991 Nov;91(5):484-92 [1951410.001]
  • [Cites] Clin Infect Dis. 1998 Jun;26(6):1362-6 [9636863.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):569-73 [11904625.001]
  • [Cites] JAMA. 1988 Nov 18;260(19):2879-82 [3184352.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):499-505 [17033526.001]
  • [Cites] Am J Obstet Gynecol. 1997 Aug;177(2):450-4 [9290467.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):555-62 [15090810.001]
  • [Cites] J Pediatr. 1977 Feb;90(2):243-4 [63544.001]
  • [Cites] Clin Infect Dis. 2005 Oct 15;41(8):1174-8 [16163637.001]
  • [Cites] Int J Tuberc Lung Dis. 2000 Dec;4(12):1149-55 [11144457.001]
  • [Cites] J Infect Dis. 2006 Jul 15;194(2):247-55 [16779732.001]
  • [Cites] Ann Intern Med. 1993 Mar 1;118(5):363-5 [8430982.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Oct 1;37 Suppl 2:S78-87 [15385903.001]
  • [Cites] Am J Med. 2001 Jun 1;110(8):605-9 [11382367.001]
  • [Cites] Lancet. 2000 Jun 24;355(9222):2217-8 [10881897.001]
  • [Cites] J Infect Dis. 1998 Aug;178(2):544-6 [9697740.001]
  • [Cites] Adv Pediatr Infect Dis. 1996;11:187-290 [8718464.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):654-9 [16080087.001]
  • [Cites] J Infect Dis. 2004 Jul 1;190(1):37-45 [15195241.001]
  • [Cites] J Pediatr. 1993 Sep;123(3):418-22 [8394901.001]
  • [Cites] Transplantation. 2002 Jul 15;74(1):131-2 [12134112.001]
  • [Cites] J Pediatr. 2003 Jul;143(1):16-25 [12915819.001]
  • [Cites] J Trop Pediatr. 2006 Dec;52(6):451-3 [16870685.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):903-8 [12652391.001]
  • [Cites] Clin Infect Dis. 2006 Oct 15;43(8):1069-73 [